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PART I. ACUTE TOXICITY OF BROMODICHLOROMETHANE 
2 
INTRODUCTION 
There has been an increase in' governmental ·and public 
awareness of the possible deleterious effects of low level 
contaminants in food, water, and the atmosphere. 
Products and process by~products are being increasingly 
investigated for their chr'onic ·effects bec·ause of the long-
term, iow-level exposure of the general population. 
Chlorination of drinking water, a popular water 
purification process used throughout the United State~, has 
been suspected of producing by-products for many years. 
Because of advancements in chemical analytical techniques 
and sensitivity of the detecting devices, very low levels 
of a group of c'hlorinated and brominated compounds have 
been detected in chlorineMtreated water or finished 
water. 
Bromodichloroinethane is one member of this family'of 
haloforms found in chlorinated drinking water, Toxicologic 
data for many of the haloforms are scanty or nonexistent. 
The present work provides data for the acute toxicity 
of bromodic·hloromethane in the rat, thus providing s9me 
data -heeded ·for· a chronic study, Clinical signs of acute 
exposure·in the·rat to oromodichloromethane are presented 
as well as ciin:ical chemical effects. 
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of ammonia with aqueous chlorine, as a result of water 
treatment, were reported by Barnhart and Campbell, 1972. 
Bellar, et al., 1974, reported finding chloroform and 
other haloforms in chlorinated waters at levels as high as 
150 micrograms per liter (µg/l) in waters. They also 
-
suggested a mechanism for the formation of the haloforms, 
involving the oxidation of ethanol and the.intermediate 
formation 
g 
of chloral, (c1 3-c~C-H), leading to the 
production of chloroform. No evidence was given to support 
this hypothesis. 
Bunn,. et al. , 1975, tested Bellar' s proposed mechanism 
using chloride, iodide, fluoride, and bromide added to 
natural waters. Haloforms were produced for all halogens 
except fluoride, which did not oxidize. 
After initial discovery of haloforms in finished water, 
research turned to area surveys and water source. analysis. 
A joint Federal/State survey in 1975 of 83 city water 
supplies found haloforms in concentrations from less than 
1 to 366 µg/l. 
Other surveys, Bush, et al., 1976, and Nicholson and 
Meresz, 1975, in:dicated similar levels of chloroform, carbon 
tetrachloride, bromodichloromethane, and other unidentified 
compounds present in treated drinking water. 
The discovery of the haloforms. in drinking water was a 
result of· increasingly sensitive detection methods available 
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to the analyst. Methods were sensitive to parts-per-million 
(ppm) and parts-per-billion (ppb) concentration levels in 
water, yet little was known of their toxicologic 
significance to human health. Some of the compounds of 
interest or related compounds had been investigated for 
their acute toxic properties, Table I-1. 
Much of the early work reported involved industrial 
solvents, airborne vapors, industrial pollutants and volatile 
anesthetics, particularly chloroform (CHC1
3
), and carbon 
tetrachloride (CCl4). 
Early work by Kimura et al., 1971, reported lethal dose 
values resulting .in 50% population mortality, (LD50 ), in 
various age rats for 16 industrial solvents. Included were 
chloroform, 1314 milligrams per kilogram body weight (~g/kg), 
and methylene chloride, 2136 mg/kg body weight, both in 
young rats by oral gavage. Kutob and Plaa, 1962, using mice 
and a subcutaneous injection route of exposure, calculated 
LD50 values of 6455 mg/kg body weight for methylene chloride, 
3738 mg/kg body weight for methylene bromide, 3283 mg/kg 
body weight for chloroform, 1819 mg/kg body weight for 
bromoform, 30.76 grams/kg body weight for carbon tetra-
chloride, and 298 mg/kg body weight for carbon tetrabromide. 
Thompson et al,, 1974, found oral LD
50 
values for 
chloroform, 1060 mg/kg body weight undiluted and 1280 mg/kg 
6 
Table I-1. Toxicity data of haloforms and related compounds 
U.S. Department of Health, Education and Welfare, 1974 
Compound Parameter Species Route LD Value 
CHC1'3 LD50 Rat Oral 300 mg/kg 
LDLo Mouse Oral 2400 mg/kg 
LDLo Dog Oral 1000 mg/kg 
CHBr2Cl No data currently available 
CHBrC12 No data currently available 
CHBr
3 LD50 
Mouse Sub cu 1820 mg/kg 
cc1 4 LDLo Dog Oral 1000 mg/kg 
CBr4 LDLo Rat Oral 1000 mg/kg 
CH2c1 2 LDLo Dog Oral 3000 mg/kg 
CH2Br2 LD50 Mouse Sub cu 3738 mg/kg 
ClCH2cH2Cl LDLo Hamster Oral 845 mg/kg 
LD50 Rat Oral 680 mg/kg 
LDLo Mouse Oral 600 mg/kg 
LDLo Dog Oral 2000 mg/kg 
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body weight when diluted in corn oil, using young female 
rats. 
Torkelson et al., 1976, determined an acute oral LD50 
of 2000 mg/kg body weight for chloroform in young male rats. 
Bowman et al., 1978, reported oral LD 50 values in male 
mice of 1120 mg/kg body weight for trichloromethane, 
450 mg/kg body weight for bromodichloromethane, 800 mg/kg 
body weight for dibromochloromethane, and 1400 mg/kg body 
weight for tribromomethane. They found higher values in 
groups of females for every compound. 
Butler, 1961, and Slater and Sawyer, 1971, both con-
cluded that metabolism of the haloform by the enzyme systems 
was a prerequisite to their toxicity. They suggested that 
the haloform's toxicity depended directly on the bond-
dissociation energy of the halogen involved. This was given 
as the reason for increased toxicity of bromo-haloforms 
compared to chloro-haloforms. 
Kutob and Plaa, 1962, reported chloroform, bromoform, 
carbon tetrachloride and carbon tetrabromide to be potent 
hepatotoxins, and that acute ethanol intoxication increased 
mice·susceptibility to chloroform-induced liver damage by 
increasing liver lipid and thus exposing liver cells to an 
increased amount of the haloform. 
Thompson et al. , 197 4, conc.luded that no teratogenic 
effects were produced by chloro~orm at any dose tested in 
\·,'. \I 
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rabbits or rats. However, reduced birth weights were noted 
only in the highest dose groups receiving 20 or 50 mg/kg body 
weight per day. They also found marked hepatotoxic and 
nephrotoxic action with gastric erosions at levels O·f oral 
exposure or 316 mg/kg body weight/day. Renal changes were 
cha~acterized by tubular cell swelling, fatty degeneration, 
necrosis, and marked cast formation, Mild centrilobular 
hydro.pie and fatty degeneration were observed in the liver, 
Schwetz et al., 1974, reported that 100 or 300 ppm of 
inhaled_chloroform for 7 hours/day on days 6 through 15 of 
gestation produced a high incidence of fetal resorption and 
retarded fetus development in rats. 
Koch et al., 1974, supported earlier workers, Butler, 
1961, and Slater and Sawyer, 1971, in their conclusion that 
the halogen bond energy was directly related to the halo-
form's acute ·toxicity but noted that trichloromethane did 
not fit the pattern as expected and might ha.ve extrahepatic 
sites of action. 
Timms and Moser, 1975, presented their work and others, 
Stahl. et al., 1966, and Hall and Hine, 1966, wit.h accidental 
and deliberate haloform poisoning in humans resulting in 
diffuse pulmonary damage. 
Torkelson. et al., 1976, reported skin hyperemia and 
exfoliation upon dermal application of chloroform to rabbits. 
' 
Rats exposed to 85 ppm chloroform by inhalation for 144 days, 
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(7 hours of exposure per 24 hours), had normal serum 
pyruvate transaminase (SGPT), blood urea nitrogen (BUN), 
and serum alkaline phosphatase (ALK, PHOS.) levels, despite 
marked central lobular degeneration of the liver. 
Ahmed et al., 1977, studied the evidence to support 
the hypothesis that the haloforms are metabolized to carbon 
monoxide via a cytochrome P-450-dependent mixed function 
oxidase system, and also found the degree of metabolism was 
related to the bond dissociation energy of the halide 
involved. 
Bowman et al., 1978, found fatty infiltration, pale 
kidneys and hemorrhages in the brain, lungs, and adrenal 
glands following oral exposure in mice to trichloromethane, 
bromodichloromethane, dibromochloromethane and tribromo-
methane. 
Brown et al., 1974, concluded that chloroform hepato-
toxicity occurred when haloform exposure significantly 
reduced the glutathion levels in the liver to the point that 
continued exposure produced free radicals, which covalently 
bound the microsomal protein. Also, it was suggested that 
an autocatalytic lipoperoxidative reaction led to cellular 
necrosis (destruction of phospholipid-rich intracellular 
membranes), and triglyceride accumulation. 
Docks and Krishna, 1976, found no glutathion 
reduction after exposure to carbon tetrachloride and 
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bromotrichloromethane. They concluded that glutathion 
depletion must be due to formation of metabolites other than 
the trichioromethyl free radical. 
Finally, Roe, 1976, and researchers at the National 
Cancer Institute, 1976, identified chloroform and tri-
chloroethylene as carcinogenic in at least one species, and 
several other haloforms were considered prime suspects. 
Morris, 1975, presented an excellent review of aqueous 
chlorination chemistry. Chlorine chemistry in water 
involved reactions of hypochlorite rather than the chlorine 
itself because of an almost instantaneous and complete 
hydrolysis according to eq. I-1. 
+ HOCl + Cl + co2 
HOCl '!: H+ + OCl -
The hypochlorite will participate in four principal 
types ~f reactions: 
(1) addition to olefinic bonds 
R1 -C.H=CH-R2 + HOCl -·-· > R CH-CH-R 11 I. ? 
(2) activated ion substitution 
·®' . + HOCl -> 
OH 
or 
Cl OH 
0 
11 
+ HOCl -> CH Cl-C-CH 
2 3 
(I-1) 
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(3) oxidation with reduction of the hypochlorite 
to chloride 
0 0 
II II + 
R-C-H + HOCl -> R-C-OH + H + Cl 
(4) and substitution of chlorine for hydrogen in 
a nitrogen atom, as reported by Barnhart and 
Campbell, 1972. 
Of particular interest to haloform research is the haloform 
reaction, which generally occurs in alkaline solutions of 
acetyl-bearing compounds, CH
3
-C=O, or alcohols which can 
be oxidized to acetyls. 
By successive replacement of hydrogen with halide, 
mono, di, and tri halogenated compounds are formed, eq. 2-8. 
0 
" kl R-C-CH
3 
--> 
0-
1 + 
R-C =CH
2 
+ H 
0- . k 
R-b=cH2 + CH2 + HOCl -
2-> 
?i k3 ~ 
R-C-CH
2
Cl --> R-C=CHCl + H+ 
0 
I k4 
R-C=CHCl + HOCl --> 
0 
I 
R-C=CC12 
0 
II 
R-C-CC1 3 
k6 
+ HOCl --> 
- + cc1
3 
+ H 
~ 
R-C-CHC1 2 
0 
II 
R-C-CC1 3 
0 
II 
R-C-OH + cc1
3 
(I-2) 
(I-3) 
(I-4) 
(I-5) 
(I-6) 
(I-7) 
(I-8) 
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K1 is much slower than all other reaction rates and is the 
rat.e ·determining step for the whole haloform reaction. 
Brominated products were produced depending on the 
ratio of chlorine to·bromine in solution. Ethanol, 
acetaldehyde, methyl ketones, and secondary alcohols are 
examples of compounds subject to haloform reactions. 
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MATERIALS AND METHODS 
Materials 
Test animals 
Male and female Sprague-Dawley specific pathogen free 
1 
rats were purchased from the Blue Spruce Farms, Inc. Ten 
week old animals with mean body weights of approximately 
220 grams (g) for females and 320 g for males were used. 
Dosing reagents 
Bromodichloromethane, purity greater than 97%, was 
obtained from Aldrich Chemical Co. 2 Purity was verified by 
low temperature gas-liquid chromatography, using 0.2% 
Carbowax 15003 liquid phase on carbopack 100/120 support at 
l00°c. 
Reagent grade propylene glycol, Baker Chemical Co., 4 
was used as a dosing vehicle. Electron-capture gas 
chromatographic analysis of the propylene glycol showed no 
halogenated compounds in detectable concentrations,~.~., 
less than 1 part-per-million, ppm. 
1 Blue Spruce Farms, Inc,, Altamont, New York. 
2Aldrich Chemical Co., Milwaukee, Wisconsin. 
3Supelco Co., Bellefonte, PA. 
4Baker Chemical Co., Chicago, Illinois, 
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Feed, housing, and supplemental supplies 
Wayne Lab-Blox®, a commercially available lab animal 
1 feed, was obtained from Allied Mills, Inc. Feed proximate 
analysis values were 24% protein, 4% fat, 4.5% fiber, and 
all required vitamins and minerals, as specified by the 
National Academy of Science, 1972. 
Wood shavings used for bedding were obtained from the 
Laboratory Animal Resources group within the Iowa State 
University College of Veterinary Medicine, 
Stainless steel shoebox style rodent cages were used 
throughout the studies. Inside dimensions of the cages 
were 12 inches long, 12 inches wide and 7 inches deep, 
with overhead food and water holders. 
Methods 
General 
T-he· rats were acclimated for 2 weeks after receiving 
them. Animals were housed 2 per cage in the initial screen 
test a_nd 3 per cage in the later LD50 test. All animals 
received food and. water ad lib. Temperat~re, humidity, 
noise, -and other environmental -.conditions were maintained 
at constant levels throughout the study, The animal rooms 
were lighted 9 hours out of each 24 hours. 
I ® Wayne Lab-Bl ox , Allied Mills," Inc .. , Chicago, Illinois. 
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Animal weights were obtained using a single pan dis-
placement balance with dampened movement. Accuracy of body 
weights was ±0.5 grams due to animal movement during 
weighing operations. Weights were obtained before dosing 
to determine the dose volume, and at death of necropsy. 
All animals were tattooed on the tails, using indelible 
ink, with the study designations, their dose levels and 
their individual identification numbers. An example of rat 
number 1 from the 1600 mg/kg dose group in the initial or 
prescreen test would be P-16-01. The LD study was desig-
nated by L in place of P. 
Solutions for dosages were prepared on the day of 
administration and mixed on a magnetic stirrer for at least 
1 hour prior to administration. 
Doses were administered by oral gavage using a curved 
dosing needle and disposable 3 milliliter polyethylene 
syringes. 
The dose volume administered was based on the actual 
rat weight to insure equal vehicle administration as well as 
bromodichloromethane per gram of body weight. Every rat 
received 1 ml dose/110 g·body weight. 
Rats were lightly anesthetized by exposure to diethyl 
ether prior to dosing or bleeding to reduce the possibility 
of death from aspiration or cardiac tamponade. Both control 
·and dose groups were treated identically. 
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Initial screen 
Six dose groups and a control group of 3 males and 
3 females each were used to initially define the range of 
toxicity. Doses in mg/kg body weight were 100, 300, 900, 
2700 and 8100, plus a control group which received propylene 
glycol only. Each animal was weighed, dosed according to 
its weight at a rate of 1 ml dose/110 g body weight, and 
observed for 14 days. Animals were caged 2 per cage and 
the sexes were segregated. 
Clinical signs were observed and noted on a special 
form, Form 1, throughout the study. Animals which died were 
necropsied immediately, Surviving rats were killed by 
exposure to water saturated diethyl ether and necropsied 
after 14 days. Samples of blood were collected by heart 
p-uncture in heparinized tubes, 1 when possible, and 
immediately stored at -10°C. Liver,- kidney, brain and lung 
were collected from all rats for histologic examination. 
In addition, eye, stomach, adrenal gland and sciatic nerve 
were collected in represerttative animals of each group of 
the prescreen study, Tissues were fixed in 10% neutral, 
buffered formalin, processed by routine paraffin technique 
and embedded in Altman's paraffin mixture consisting of 
Co., 
1vacutainer blood collection tubes, Becton-Dickinson 
Rutherford, New Jersey. 
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beeswax, and 100 parts steric acid. Seven micron tissue 
sections were cut. Mayers routine hematoxylin and eosin 
staining procedures were used, 
Blood, liver, kidney, and brain were collected and 
stored at -10°c for later chemical analysis for bromodi-
chloromethane. Record of collected tissues was made 
on Form 2. 
LD
50 
study 
Six groups of 9 male and 9 female rats per group 
were used to define the LD
50 
in the rat. Doses in mg/kg 
body weight were O, 400, 800, 1600, 3200 and 6400 bromodi-
chloromethane administered in propylene glycol. Animals 
were caged 3 per cage. Dosing was again done by weight, 
1 ml/100 g body weight, and observation was maintained 
for 14 days. Necropsy and sampling procedures were as 
previously defined. Specimens were collected and stored 
at -10 C for later chemical analysis or fixed in 10% 
neutral, buffered formalin and processed as previously 
described. Record of collected tissues was entered on 
Form 2. 
Data collection 
Individual animal data and observations were 
collected and recorded on Forms 1 and 2. The forms for 
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prescreen rat number 1, dose level 900 mg/kg, are set out 
herein identified as Forms 1 and 2. 
Blood chemistry methods 
Two groups of 9 female Sprague-Dawley rats were 
acclimated, housed, fed and cared for according to 
procedures already described. One group was dosed with 
1200 mg/kg bromodichloromethane in propylene glycol. The 
other group served as a control group and received 
propylene glycol only. BUN was chosen to monitor renal 
function. SGPT, ALK, PHOS, and serum albumin were used 
to monitor hepatic functions. 
Initial blood profiles for the 4 tests were con-
ducted in all animals prior to dosing. A second survey 
was conducted at 48 hours post dose administration when 
signs were evident in the majority of the dose group. A 
final survey was conducted on the surviving animals on 
the 14th day post dose. Each survey included both the 
control and dose group. 
Blood was collected by heart puncture using a 22 ga. 
disposable needle and a 3 ml disposable syrings. The 
blood was immediately transferred to a capped test tube 
and allowed to clot. The serum was separated from the 
clot with centrifugation. Clinical chemistry analyses 
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Form 1 
Form 1 was used to record daily observations for each 
individual rat. 
-· 
-· 
.. 
.J • 
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ON IHI\!, Nt,\.IOll'!H timp 
Toxicology Sect ion; Veter lnary Dla"nosl lc Lnboratory; lOWA STATE UN IVERS tTY. Ames, lowa 
PrnJ. Tent Spccles Anlmul ld. lllll'P 
Code Type H.epl. Grp. 
_e_ 3-. 
5 -1. --- - •tt• I 2 3 '• 6 1 
Veterinarian(s) 
i41516Ti, W£. 
Tcchnician(s) w~L 
Tissue Code 0 ,; SYSTEM: t!RSUP Wt. Tissue C:ode Q SYSTEM: tissue Wt. u u m • • • 9 ·ro rr i2 rJ ~ ,, .; iO fl fi r- : ti "' u 
INTEGUMENT ,!JROGENlTAL 
hair ,/ 'v kidney 
skin ureter 
fat (subcutan.) bladder 
lymph nodes urine 
testicle 
MUSCULOSKELATAL epididymis 
bone ductus deferens 
prostate 
joint 
bulbourethre 
seminal vesicles 
penis 
muscle prepuce 
ovary 
RESPIRATORY oviduct 
nasal cavity uterus 
larynx cervix 
trachea 
vagina 
bronchi vulva 
pleura mammary l~land 
v lungs 
thoracic cav. 
CARDIOVASCULAR lymph nodes 
blood, EDTA 
1.v .. blood, Heparin 
DIGESTIVE blood, clot 
oral cavity 
heart tongue 
spleen teeth 
saliv."lry gland artery 
pharynx vein 
esophagus thoracic duct 
atidominal cav. 
peritoneum 
:-""' 
~ERVOUS 
,/ stomach v cerebrum 
duodenum ~ ~=~=~e~~::· jejunum v "~ 
ileum .,/ .... t-- medulla 
cecum spinal cord 
colon cranial n. 
rectum· v fterye . 
anus . .SC.1-i•C.. 
. .,.. v pancreas special sense .,,. liver ...-- f:~c: 
fat (abdominal) ENDOCRINE 
lymph node ....- adrenal 
---· thyroid feces thymus 
pituitary 
Rcc.nrd GROSS and llISTOPATHOLOG[CAL observations on reverse side. ( :i .~ " ) 
Form 2 
Form 2 was used to record tissues collected from each rat. 
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were conducted irrunediately using an American Instrument Co. 
Rotoche~ 1 analyzer. 
A Student ''t'' test was used to determine if there was 
a significant difference between the 2 groups of blood data, 
or if they actually belonged to the same population. A 
certainty condition minimum was set at the 95% confidence 
level, p=.05. 
Statistical methods 
Several methods of analysis were available for 
calculating the LD50 of bromodichloromethane. 
The dose level, the number of animals per group and 
the number dying during the 14 day observation period, were 
used in the method of Litchfield and Wilcoxon, 1949, and 
also in the statistical analysis system2 computer program 
available at the Iowa State University Computation Center 
through the Analysis Of Variance (ANOVA) procedures and the 
probit procedures (PROC PROBIT). 
1American Instrument Co., Rotochem Analyzer,@) 
Silver Springs, Maryland. 
2
PROC PROBIT and ANOVA are operating at Iowa State 
University within the Statistical Analysis System under 
license from the SAS Institute Inc., P.O. Box 1006, 
Raleigh, NC. 
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RESULTS 
Clinical Results 
Clinical signs observed in the 8100 mg/kg initial 
screen animals commenced within an hour of dosing (0 hr). 
At 1 hr post dose, animals had loss of coordination with 
lessened response to external stimuli. Dosed rats lost eye 
color compared with the control rats. The dosed rats 
rapidly became moribund, but retained some muscle tone. 
There was no response to external stimuli. The next phase 
was signaled by the presence of a completely limp body. 
Respiration went from normal at 0 hr to very rapid and 
shallow at 1-2 hrs post dose. Breathing further slowed 
after 2 hrs post dose to a very slow dyspnic breathing just 
prior to death. 
The 2700 mg/kg dose group in general were sluggish 
and incoordinated at approximately 2 hrs post dose. They 
were totally debilitated with no response to external 
stimuli at 4 hrs post dose. Very rapid shallow breathing 
was noted at 10 hrs post dose. Survivors had lessened 
clinical signs. Sluggishness and breathing both improved 
from 1-2 days post dose until the end of this study. 
The 900 mg/kg group had first signs 3 days post dose. 
They appeared nervous with rapid breathing. They seemed 
somewhat depressed and developed very rough hair coats. 
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Petechial hemmorhages were present in the foot pads of some 
of the rats. The rat's general appearance improved after 
4 days. Some rats had red, irritated, swollen snouts and 
oral mucous membranes. 
The 300 mg/kg group had very mild clinical signs 3-4 
days post dose. Some had slightly pink oral mucous 
membranes and feet and others developed a rough, uncared-for 
appearance. 
Both the 100 mg/kg group and the control group had no 
clinical signs throughout the 2 week trial. 
Gross lesions were observed during necropsy in some-of 
the rats receiving higher dose levels. Livers were dark 
brown and the subcapsular surface of the kidneys was 
mottled dark brown, There was a general loss of color in 
the lungs of the dosed rats to a pale flesh color at death 
compared to lungs of rats in the control group, Subdural 
hemorrhage was noted in many rats of the 3 highest dose 
_groups. Stomach contents varied from full of feed to empty, 
with the animals dying early generally having the fullest 
stomachs, Many of the 2 or 3 day fatalities had empty, 
contracted stomachs, Blood was noted in the urine of a few 
1600 mg/kg dosed rats. 
Signs observed in the LD50 study were nearly identical 
to the initial atudy at the various dose levels. One 
discrepancy appeared at 4 days in several of the 800 and 
1600 mg/kg male rats. During the night, 7 of 18 rats were 
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found dead wedged between the cage and lid, or were found 
dead on the floor. No similar instances occurred before or 
after in any of the studies. 
LD50 statistical results 
The LD
50 
values for bromodichloromethane in male rats 
by oral gavage were 1633 mg/kg body weight with confidence 
intervals (CI) at p=.05 of 814 to 3089 mg/kg using the SAS 
PROC. PROBIT procedure, and 1740 mg/kg body weight with CI 
of 800 to 3900 mg/kg using the method of Litchfield and 
Wilcoxon, 1949. 
The LD 50 value in female rats was 1504 mg/kg body 
weight with. CI of 1116 to 2255 mg/kg at p=.05 using the 
SAS PROC. PROBIT procedures. 
The LD50 of the total population, disregarding sex, was 
1580 mg/kg body weight with CI at p=.05 of 1256 to 2011 
mg/kg, using the SAS PROC. PROBIT procedures. 
The LD50 of the total screen and LD 50 
study combined 
population, disregarding sex, was 1706 mg/kg body weight, 
using the SAS PROC. PROBIT system. 
The ANOVA study resulted in an insignificant F value 
for animal weight at the time of dose and sex, Dose level 
received and time (hours-to-death) were both found to have 
significant F values at p=,05. 
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Clinical Chemistry Results 
Results for the clinical chemistry values in the control 
group and dose group were compared statistically. Table I-2 
summarizes the results of blood chemistry analyses at 3 
sampling times: before dose, after dose at 48 hours, and at 
the conclusion of the 2 week observation period, Table I-3 
represents the pertinent statistical results of the study. 
None of the control group chemistries differed from 
the dose group results prior to dosing, at the p=,05 level. 
BUN was affected statistically, p=,05 or lower, by the 
administered dose at the 48 hour testing. Neither SGPT, 
serum albumin, nor ALK. PHOS. showed differences between the 
control and dose groups at t.his time. 
All 4 blood chemisj;ry analyses did show a significant 
· statistical difference between the 2 groups after 2 weeks 
at the p=,05 significance level, 
Histopathology Results 
Tissue sections were referred to a certified 
veterinary toxicologist1 and were not completed, The experi-
ence and judgement necessary to evaluate histologic changes 
i.n tissues was not deemed fundamental to the present study. 
1Dr. W. E. Lloyd, Veterinary Diagnostic Laboratory, 
Iowa State University, Ames, Iowa. 
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Table I-2. Blood chemistry results - 1200 mg/kg dose 
Time 
b ALK. PROS. Albuminc 
Control Dose Control Dose Control Dose Control Dose 
14.6 19.9 75,6 108.4 4.5 4.7 
4.7 
24.o 17.0 
0 hr 23.2 26.5 79,8 168,o 
193.0 
4. 5 
4.8 
4,4 
4.2 
18.8 19.0 
14.o 17.4 
18.1 15.1 186.7 124.2 4.5 4.9 15.0 19.0 
15.4 
16.o 
16.3 
17.4 
13.2 
9.7 
21.2 
48 hr 47.8 
25.3 
15.8 
18.0 
18.1 
20.5 
15.9 
19.9 
16.9 
14.9 
13.7 
33,9 
13.8 
21.1 
27,6 
142.5 
81. 4 
176.8 
101.1 
176.8 
109.7 
93,6 
78,5 
163.0 
91. 6 
142.6 
134.2 
21.2 131.9 79,3 
47.8 130.1 104.7 
116.1 
25.3 162.9 180.5 
15.8 170.0 105.6 
207.5 
142.5 
4.9 
4,4 
4.2 
4.3 
4.4 
4.8 
4.8 
4.4 
5,1 
4.4 
4.6 
4.7 
5.0 
4. 3 
4.7 
4.5 
4.4 
15.0 
12.0 
19.0 
25.0 
15.0 
5.1 25.0 
4.7 19.7 
25.6 
4.5 23.0 
3,8 22.3 
25.3 
aSGPT expressed in IU of enzyme activity, 
bALK. PROS. expressed in IU of enzyme activity. 
cAlbumin expressed in g/dl, 
d BUN expressed in mg/dl. 
21. 9 
17.1 
19.8 
23.7 
16.0 
16.5 
17.1 
18.4 
16.0 
19.9 
20.1 
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Table I-2. (Continued) 
Time SGPTa ALK. PROS. 
b Albuminc BUNd 
Control Dose Control Dose Control Dose Control Dose 
14.9 13.2 56.4 103.8 5.0 4.8 20.2 15.1 
16.4 37.3 86.3 5.3 4.7 21. 8 18.4 
14 17.4 12.5 78.1 73.1 5.6 4.7 22.1 20.6 
days 16.9 12.2 72,6 
14.3 50,5 5.4 18.3 
18.9 83.5 5.1 24.4 
5.1 20.9 
15,6 63.5 5.5 22.9 
12.i 48,6 5,5 22,8 
Table I-3. Blood chemistry statistical results 
Dose 
Pre dose 
SGPT 
Not significant 
at p=.05 
t = 1. 85 
with 16 df 
48 hr Not significant 
post dose at p=.05 
14 days 
t = 0.77 
with 9 df 
Significant 
at p=.05 
with 9 df 
dose level 
depre.sseda 
ALK, PHOS. 
Not significant 
at p=.05 
t = 0.63 
with 17 df 
Not significant 
at p=,05 
t = 2.0 
with 9 df 
Significant 
at p=.05 
t = 2.7 
with 9 df 
dose level 
elevateda 
Albumin 
Not significant 
at p=.05 
t = 0.75 
with 17 df 
Not significant 
p=.05 
t = 0.77 
with 9 df 
Significant 
at p=.05 
t = 4.5 
with 9 df 
dose level 
depressed a 
aDose blood level was compared with control blood level, 
BUN 
Not significant 
at p=.05 
t = 1. 51 
with 17 df 
Not significant 
p=.05 
t = 4.67 
with 9 df 
dose level 
depresseda 
Significant 
at p=.05 
t = 2.86 
with 9 df 
dose level 
depressed a 
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The histologic examination was not complete but will 
be presented in other publications. 
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DISCUSSION 
The rats were divided into groups, dosed, and 
observed. A model describing the relationship between 
effect and dose was formulated. The model also included 
other variables, ~.g., sex and dosed body weight. 
Equation 9 outlined the suspected relationships 
between effect (dead or alive), and the variables, sex, 
weight, and dose. 
Effect = dose factor (dose level) + sex 
factor (sex) +weight factor (wt) (I-9) 
For statistical analysis, equation 9 became 
equation 10 
Y = u +di + b (wti - wt) + c (sex) + e (I-10) 
where y1 = observed or predicted effect 
u = overall mean 
di = effect due to dose level 
b (wt 1 - wt) = effect due to different 
animal weights 
c (sex) = effect due to different 
sexes 
e = error in model 
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If each sex was considered separately in a group then 
eliminating c (sex) was justified and-equation 11 was 
justified: 
(I-11) 
In this manner, it was possible to test the significance 
of dose-to-effect, and weight-to-effect directly; and 
sex-to-effect by comparison. 
Using an "F" test or analysis of variance, it was 
possible to examine data and conclude whether a variable 
was significant and necessary to the model or merely 
occurred randomly due to chance, Since an arbitrary 
boundary had to be chosen for what was significant and 
what was not, a value of P = .05 was chosen as the 
break~off point of significance. 
Of initial interest was analysis of how randomly the 
animals had been assigned to the different dose groups. 
1f the animals had been randomly assigned, each group would 
be expected to behave or respond similarly to an external 
stimuli.. If; however, 'the groups were dissimilar by weight, 
breeding,'or some other factor, they might have been 
expected to respond dissimilarly, thus affecting the 
significance of variable testing results. In this study, 
due to the nature of the breeding, weight appeared to be 
the most probable.source of init~al bias, The results of 
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the Analysis Of Variance (ANOVA), see Appendix, for the 
dependent variable, weight, between dose groups supported 
the hypothesis that both sexes had been randomly assigned. 
The males showed 9% prob > F while the females showed 
8G% prob > F, This disparity was attributed to the small 
number of observations at each dose level. Examination of • 
the individual weights among the males showed that one group, 
16GG mg/kg, had an extremely low group mean weight due 
primarily to 2 light weight members. The ANOVA results 
proved weight to be random between animals and allowed the 
simplified equation 12 to be used, eliminating the consider-
ation of weight effects, The General Linear Models procedure 
yij = uj + dij + ej (I-12) 
(GLM) was used to test the hypothesis that the dose was a 
significant variable in equation 12. The relationship 
between effect and dose was analyzed in 2 ways. First, the 
quantal, dead or alive, response versus dose level was 
checked. Second, the hours-to-death, (HTD), and reciprocal 
HTD, (RHTD), were analyzed as a function of dose level. 
The ''F'' test results, see Appendix, proved a very strong 
effect dependence on dose when the analysis was considered 
both ways. Both the F test for quantal comparison and the 
HTD or RHTD confirmed the hypothesis that dose was a 
significant variable to be considered. 
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The results supported equation 12. To actually define 
equation 12, the PROBIT procedure was used, as well as the 
older classical procedure of Litchfield and Wilcoxon, 
1949. The PROBIT procedure used the doses, the total number 
of rats per dose group and the percent mortality in each 
dose group to produce a relationship between the mortality 
and dose. Since all other variables had been eliminated, 
this program was justified, 
As discussed previously, the sexes were separated and 
analyzed in 2 groups. Both groups showed high dose-to-
effect correlation. Figure I-1 shows mortality as a 
function of dose for both sexes, as calculated by the PROBIT 
procedure, SAS, The graph illustrates the overlap of 
confidence intervals of LD values for the two sexes. It 
would be very difficult indeed to conclude that there were 
sex differences in dose-effect from this data due to. the 
extremely small numbers of observations taken, and the 
correspondingly large confidence interval values, Larger 
groµps of animals would produce finer definitions of the 
confidence intervals of the functions allowing a valid con-
clusion of whether there were sex differences. The PROBIT 
procedure calculated the LD50 values to be 1633 mg/kg body 
weight for males and 1504 mg/kg body weight for females. 
The confidence intervals were ±69% and ±88% of the LD value. 
The manual method for Litchfield and Wilcoxon, Appendix, 
Figure I-1. Mortality versus dose 
Note the almost complete overlap of male --<:)- and female ~ 
confidence intervals, making differentiation between sexes 
difficult 
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produced an LD
50 
for males of 1740 mg/kg body weight with 
CI of ±43%. The manual method for females was seriously 
hampered due to limited data between 0 and 100 per cent 
mortality. The PROBIT procedure was used on the data as a 
whole, disregarding sex, since it was shown to be an 
insignificant factor. The LD
50 
in 10 week 6ld Sprague-Dawley 
rats was 1581 mg/kg with CI of +21%,-28% of the LD50 . 
Lastly, the time effect of dosing bromodichloromethane 
was of interest. What effect, if any, did the dose level 
have on how fast death occurred? Figures I-2 and I-3 
illustrated per cent mortality in each dose group as a 
function of time. Clearly, there was a relationship and 
using the GLM procedures, its significance was tested. 
Both hours-to-death and reciprocal hours-to-death resulted 
in an F value supporting the hypothesis that there was a 
high positive correlation between dose and death. This 
relationship was predicted in Figure I-4 for acute oral 
exposures using average hours-to-death, Again, due to the 
small nature of the present study, confidence intervals 
were large on these values. However, the least square 
means agreed excellently with the actual observations, 
Table I-4. 
The results of the clinical chemistry analyses did not 
support a conclusion that bromodichloromethane was acting as 
either a hepatotoxic or nephrotoxic agent. The statistical 
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80 
1600 mg/kg 
% Total 60 
J\fortali ty 
40 800 mg/kg 
20 
10 24 48 72 96 120 144 168 192 216 240 288 336 
Hours-to-Death 
Figure I-2. Observed mortality rate as a function of dose for females. Each 
line represents a dose's actual mortality rate as a function of 
time. Note that all effects of a single oral dose seem to 
display themselves by 120 hours, The study was terminated at 
336 hours 
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Figure I-3. Observed mortality rate as a function of dose for males. Each line 
represents a dose's actual mortality rate as a function of time. 
Note that all effects of a single oral dose again seem to display 
themselves by 120 hours. The study was terminated at 336 hour.s 
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Table I-4. Comparison of calculated least square and 
observed hours-to-death (HTD) 
Dose Sex 
0 F 
M 
400 F 
M 
800 F 
M 
1600 F 
M 
3200 F 
M 
6400 F 
M 
HTD Observed 
336.00 
336.00 
336.00 
336.00 
155.00 
245.33 
118.33 
183.44 
58.56 
11. 33 
12.67 
8.67 
Least Square 
HTD Calculated 
324.19 
338.42 
329.75 
335.26 
157.88 
243.75 
135.31 
182.87 
64.77 
10.21 
4,62 
10.72 
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Student ''t" tests between the dosed group results and the 
control group results showed statistically significant 
differences in all 4 blood chemistry analyses, p=.05, at 
2 weeks post dose, Table I-3. However, the control group 
blood levels did not differ from the dose group levels 
enough to be of diagnostic significance. 
Compiled data by Melby and Altman, 1974, were used to 
determine that blood chemistry results in the control groups 
were within normal ranges as reported by other workers. All 
4 blood chemistry analyses were in good agreement with 
workers cited by Melby and Altman. 
ALK. PHOS. was used as a monitor for liver injury. The 
:('.esults of the clinical chemistry analyses for ALK. PHOS. 
showed a statistical difference between the dosed group and 
control group at 48 hrs and 2 weeks post dose, However, the 
average blood ALK. PHOS, levels differed by only 20% between 
• 
the 2 groups. Since ALK. PHOS. levels generally fluctuate 
more than this in normal healthy populations, no clinical 
significance was attributed to the findings. 
SGPT was also used as a liver injury monitor. SGPT 
differed statistically at 2 weeks from the control group but 
not at 48 hrs post dose, However, again the differences 
between the 2 groups were within the normal ranges expected 
in healthy individuals. Control and dosed group chemistry 
levels were in agreement with data collected by Melby and 
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Altman, 1974, for normal animals, and thus showed no evidence 
of a hepatotoxic mode of action. 
Serum albumin was also used as a monitor of liver 
injury. Serum albumin levels were statistically different 
between the two groups but the difference again was not 
considered to be of diagnostic significance. Therefore, 
serum albumin results did not indicate hepatotoxic injury. 
BUN was used as a monitor of renal function. BUN in 
blood differed statistically at both 48 hrs and 2 weeks post 
dose from the control group levels. However, the values 
obtained all fell well within normal ranges and were not 
considered diagnostic of a nephrotoxic mode of action. 
The clinical chemistry data were limited. Because of 
the size of the groups and the health of the dose group 
during the last 2 blood samplings, the number of samples 
available for chemistry and statistical analysis was smaller 
than originally hoped. Also, some difficulty was experienced 
in bleeding the animals without killing them. A minimum of 
2 ml of nonhemolyzed blood was required to provide the 
necessary 1 ml of serum for the 4 blood analyses. Even after 
repeated attempts, to the point of endangering the animals' 
lives, adequate blood was not obtained in a few cases, 
resulting in only 3 or 4 samples for statistical analysis. 
As the number of data got smaller and smaller, the certainty 
or precision of the statistical analysis decreased 
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accordingly. As has been pointed out, statistical signifi-
cance does not necessarily indicate diagnostic significance. 
One factor of the LD
50 
study was especially perplexing. 
At 4 days post dose, 7 of 18 male rats in the 800 and 
1600 mg/kg dose level groups were found dead. The rats 
had climbed halfway out of their cages and died with their 
bodies bent over the edge of the cage. half in, half out, 
or were found on the floor of the animal room. Dr. Ronald 
Flatt and Mr. Ronald Moses, both experienced in rodent 
testing, have not encountered this problem with the cage 
used or any breed of rat. These rat deaths were discounted 
in the statistical workup. The deaths may reflect behavior 
effects that should be considered in future studies. 
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SUMMARY 
Acute death.due to bromodichloromethane was clearly 
dose-related. Weights of animals in groups were found to be 
randomly assigned. The data were insufficient to conclude 
that sex contributed significantly to the model. A study 
involving large numbers of animals could answer this question 
more precisely. 
There was a definite relationship between hours-to-death 
and dose level. Although not tested specifically, it was 
obvious during observation that order of appearance and 
severity of clinical signs were dose-related also, Clinical 
signs included incoordination, weakness, depressed 
respiration, and depressed appetite. 
Post mortem examinations of dosed rats revealed pale 
lungs, mottled kidneys, subdural cranial hemorrhage, 
hemorrhage of foot pads, and dark brown livers as compared to 
the control group. Clinical chemistry analyses did not show 
a diagnostic difference between the dose and control groups 
and did not give evidence for a simple nepho- and hepatotoxic 
mode of action for bromodichloromethane. However, numbers 
of sa~ples in the clinical chemistry study dwindled from 
10 rats per test group to 3 or 4 per group in the 48 hr and 
2 week testing due to sampling difficulties and death of 
the subjects. The blood chemistry study should be done with 
large~ groups of rats over a longer period of time, possibly 
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a chronic exposure study. The LD
50 
for the total population 
was 1581 mg/kg body weight with CI of +21%, -28%. Due to 
the small number of animals observed, the 95% confidence 
intervals on the LD values are large. A study involving 
a larger number of subjects than in the present study is 
needed to seriously use the LD 01 value from the statistical 
procedures. Also, the doses used should be geometrically 
spaced between 500 and 2500 mg/kg for a mortality spread of 
5% to 95% mortality. Also, the unexplained behavior of the 
800 mg/kg and 1600 mg/kg groups should be reinvestigated 
for possible CNS or behavior effects. 
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PART II: CHEMICAL ANALYSIS OF BROMODICHLOROMETHANE 
48 
INTRODUCTION 
Chemical analysis of trace contaminants has been an 
increasing concern in recent years because of an awareness 
of their detrimental effects on people or animals exposed 
over long periods of time. Halogenated methane 
derivatives (haloforms) and homologs have been investigated 
since their discovery in drinking water by Kleopfer and 
Fairless, 1963. However, the majority of the chemical 
analysis methods have dealt primarily or solely with the 
analysis of haloforms in water. 
Little research has been directed to the problems 
surrounding the analysis of the halof orms in biological 
tissues and fluids, The present study provides 
methodology for the routine extraction of bromodichloro-
methane from blood, liver, kidney and brain and its 
quantitation using gas-liquid chromatography, Interferences 
and recovery data for the methods are included. 
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REVIEW OF PREVIOUS WORK 
Rook, 1972, developed a static gas head-space analysis 
method in which 10 ml of water were heated for 12 hrs 
after which the head-space gas was forced through a small 
trav of activated silica gel. The organic compounds were 
eluted from the trap and separated by gas chromatography, 
Rook's work was with lower alkanes, freons, chlorinated 
solvents and substituted benzenes. 
Mieure and Di~tri6h, 1973, developed procedures for 
sa'mpling air or water for trace organics. They relied on 
a salting-out effect using sodium chloride to decrease the 
solubility.of haloforms and other organic compounds in 
water. They used methylene chloride to extract the less 
v'ol.atile components of finished drinking water. 
For mpre vplatile compounds, Mieure and Dietrich used 
gas §tripping t~chniques with collection of the organics 
·on Tenaft> .1 gas chromatographic (GC) packing in tubes. 
This trapping _tube was then directly connected to the gas 
cl):f.omatpgraph ··and ·thermally transferred onto t_he GC column 
.to be separated and.identified,. They also investigated 
the possibility of 
Chromosorb 102®. 1 . ' . 
direct resin column collection using 
The water sample was fed through the 
1Tenaft> column packing ~nd Chromosorb 102® co_lumri 
·packf~g available from Supelco ,_ Inc .. , Bellefonte, PA. 
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column.packing, the packing was dried, and then the column 
was connected directly to the gas chromatograph and the 
temperature programmed. 
Glaze et al., 1973, used XAD-fi> 1 resin, a macro-
reticular resin, to extract and trap organics from large 
volumes of chlorine-treated sewage water. Diethyl ether 
or acetone was then used to elute the trappe~ organics 
from the resin column. These eluents were further conc·en-
trated for gas chromatographic separation and mass 
spectroscopy structural identification. Glaze's work 
was limited to organic phenols and other relatively non-
volatile compounds, since his concentration step lost many 
of the volatile components. 
Grob, 1973, reported a continuous loop, recycling 
gas-stripping process followed by collection on charcoal. 
The charcoal trap was then eluted with carbon disulfide. 
Bellar and Sigsby, 1970, and Bellar and Lichtenberg, 1974,· 
used gas stripping and resin column trapping to collect 
volatile water contaminants. Various trapping materials, 
silica. gel, Porpak QlY, 2 Chromosorbs®, and TenaflD were 
compared for trapping effectiveness. Using these 
1
XAD-2 resin, Rohm and Haas, Philadelphia, PA. 
2p R · 
orpak column packing, Supelco, Inc., Bellefonte, PA. 
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techniques, Bellar, Lichtenberg, and Kroner, 1974, found 
unequivocal qualitative identification of chloroform, 
bromodichloromethane, and dibromochloromethane in 
laboratory tap water. Various untreated' w~ters were 
tested with levels of these 3. contaminants ranging from 
1 to 152 ppb. 
Junk et al,, 1974, proposed a method for large. sample 
testings utilizing u~ to 4000 liters of water, XAD-fll' 
resin was used as a trapping material. 
Dowty, Carlisle and Laseter, 1975, used sample 
heating and helium gas stripping with resin collection to 
determine 13 halogenated hydrocarbons in drinking water 
and blood plasma from New Orleans, La. U.S..A. Blood plasma 
was collected in EDTA Va:cutainer® 1 tub~s to prevent 
clotting. Both tetrachloroethylene and carbon tetrachloride 
were confirmed.in the plasma samples, 
Kopfler et al., 1975, investigated the effects of 
heating water samples to achieve higher haloform recoveries, 
They.found both time and temperature increased the concen-
tration of halo.forms in the .water artificially. They 
· .s.uggest.ed stoping and. shipping ·samples at 4 degrees centi-
grade to prevent haloform concentration changes .. 
. , 
1EDTA Vacutainer® tubes., Becton-Dickinson Co,, 
Rutherford, NJ. 
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Nicholson and Meresz, 1975, used direct aqueous 
injection gas chromatography to analyze the haloform_s in 
water at levels of 10 ppm and below. Surprisingly, they 
reported very little degradation of the scandium tritide 
electron capture detector from the water injections. 
Bunn et al., 1975, using the Bellar and Lichtenberg-
method, 1974, reported the formation of all 10 possible tri-
halomethanes of chlorine, bromine and iodine in laboratory_ 
tests. 
Kissinger and Fritz, 1976, reported a novel approach to 
haloform analysis with resin collection on acetylated XAD-2 
resin followed by stripping iith pyridine, Chriswell, 
Kissinger and Fritz, 1916, showed that the pyridine solvent 
could b,e completely eliminated when injected on a .copper 
chloride/chromosorb column. The obvious advantage is a lack 
of a solvent peak to interfere with the very early eluting 
haloform peaks. Also,_ Kissinger suggested ascorbic acid as a 
water sample preservative to half haloform concentration 
changes d~ring sample shipment and storage. 
Richard and Junk, 1977, used pentane for liquid extrac-
tion o_f water. The resulting pentane, after being dried over 
a suitable desiccant, could be directly injected for gas 
chromatographic analysis. 
Kaiser and Oliver, 1976, modified the head space-
prbcedure by slightly-evacuating the space before thermal 
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equilibration. They claimed an improved recovery, but 
did not address the reported problems of artificially 
elevated haloform concentrations. 
Nicholson, Meresz and Lemyk, 1977, suggested that 
the direct injection technique be used to determine total 
potential haloform content of water. However, as the 
authors point out, the final concentration depends on 
temperature, pH, and other environmental factors. Also, 
total potential haloform concentrations are achieved under 
conditions unlikely to be encountered in nature so that 
potential haloform content is of doubtful significance. 
Davies, 1978, used an n-heptane liquid-liquid 
extraction of blood to determine levels of chloroform 
and other organic compounds in water. 
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MATERIALS AND METHODS 
Materials 
Chemicals 
Pentane, nanograde or distilled-in-glass quality, 
Mallinckrodt. 1 
Bromodichloromethane, purity 98%, Aldrich Chemical 
2 Company. 
Bromoform, purity 97%, Aldrich Chemical Company. 2 
Carbon tetrachloride, Baker Chemical Company. 3 
Carbon tetrabromide, purity 98%, Aldrich Chemical 
Company. 2 
1,2-Dibromomethane, purity 95%, Aldrich Chemical 
Company. 2 
1,2-Dichloroethane, Baker Chemical Co~pany.3 
Chloroform, Baker Chemical Company.3 
Methylene Chloride, Baker Chemical Company. 3 
Sodium sulfate, Baker Chemical Company.3 
1Mallinckrodt Chemical Company, St. Louis, MO. 
2 . 
Aldrich Chemical Company, Milwaukee, WI. 
3Baker Chemical Company, Chicago, IL. 
' 
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Equipment and instrumentation 
Packard model 427 gas liquid chromatograph with a 
. 1 
nickel-63 electron capture detector, 
Column packing: 0.2% carbowax 1500 on 80/100 mesh 
carbopackR, Supelco Co,, lot #F-13182, 2 
GC columns: 2 meters in length, glass. 
Graduated, glass-stoppered 15 ml Pyreffe extraction 
tubes.3 
Sorvaffe high-speed blender/homogenizer, DuPont 
Company. 4 
Glass wool, prewashed or preextracted. 
Disposable pipets, Fisher C~emical Company.3 
Glass tissue grinder with gas-stripping modifications, 
Figure II-1. 
Stainless steel resin traps, Figure II-2. · 
Thermal desorption unit, Figure II-2.5 
1Packard Instrument Co., Inc., Downers Grove, IL. 
2supelco Co., Bellefonte, PA. 
3Fisher Chemical· Company, Chicago, IL. 
4
nuPont Instruments, Newtown, CT. 
5J. Wilkes, Union Carbide, Chicago, IL, 
I 
Stripping 
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Air 
sealJng 
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Figure II-1. Gas stripping tissue grinder1 
Tissue samples were ground to a suspended aqueous 
slurry in the modified grinder. ·Nitrogen gas 
bubbling through the. slurry removed volatile 
organic compounds and swept them out of solution 
to be trap~ed and analyzed 
1Kontes, Vineland, NJ. 
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Figure II-2. Resin trap and thermal desorption apparatus 
The volatile organic compounds were swept from solution into the 
trap where they adhered to adsorbant resin. The trap was then 
connected to the probe tube, lower figure. The whole assembly was 
placed into the oven tube as illustrated in the upper figure, for 
thermal stripping of the organic compounds into the GLC inlet 
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Methods 
Analysis of biological materials for bromodichloro-
methane was approached in 2 ways. Each method had 
advantages making it appropriate in cer>tain circumstance.s. 
Each al.so had disadvantages. 
Liquid-liquid extraction - primary method 
Collection Tissues collected during necropsy were 
wrapped in aluminum foil and stored at -10°C until analysis. 
Blood samples were heparinized in stoppered collection 
tubes and stored at -10°C until analysis, Because of the 
extremely volatile nature of bromodichloromethane, all 
samples were kept frozen until immediately prior to. 
analysis, 
Blood analysis at levels of 20 ppb or greater 
Frozen blood samples were thawed, mixed with the aid of a 
vortex mixer, and sampled for analysis, One milliliter (ml) 
was volumetrically pipetted into a 15 ml glass-
.stoppered tube. Eight ml of pentane were added volu-
metrically and the' tube tightly stoppered. The tubes were 
mixed for 30 minutes on a Roto-raifID 1 at approximately 
1Roto-raJID, Fisher Instruments, Chicago, Illino.is. 
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30 revolutions per minute (rpm), After mixing, the 
pentane layer was pipetted through a mini-drying column 
made by plugging a disposable Pasteur pipet with glass 
wool and filling with 5 cm of sodium sulfate, 
Figure II-3. This pentane extract was immediately ready 
for separation and analysis by GLC using electron 
capture detection, see GLC section. 
Liver, kidney and brain at levels of 20 ppb or 
greater Two grams of tissue or, in the case of small 
animals, the whole tissue, was weighed by difference into 
a SorvalR stainless steel tissue cup, 25 ml size. Ten ml 
of pentane were pipetted volumetrically into the cup and 
the homogenizer unit assembled, The tissue and pentane 
were mixed at high speed for approximately 2 minutes. The 
pentane layer was decanted into glass centrifuge tubes 
and centrifuged at 680 x g for 10 minutes. The pentane 
extract was then dried through a mini-drying column of 
sodium sulfate stoppered and stored for gas chromatographic 
analysis. 
Gas stripping with collection - secondary method 
An apparatus described by Wilkes, 1978, was built at 
the Iowa State University Physics Instrument Shop, 
Figure II-4. A Kontes<B) tissue homogenizer was modified 
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j: DISPOSABLE PASTEUR PIPET 
Figure II-3. Mini-drying column 
GRANULAR, ANHYDROUS 
SODIUM SULFATE 
PREWASHED GLASS WOOL 
The sample extract was passed through the 
mini-drying column to remove traces of water 
prior to analysis using gas chromatography 
and electron-capture detection 
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by the Iowa State University Glass Shop for gas stripping, 
Figure II-3. 
The resin traps were filled with a mixture of 50% each 
Tenax(B), and silica gel, These were thermally stripped before 
use to insure minimum background. 
The sample to be analyzed was weighed into the tissue 
grinder. An aliquot of 2% sodium chloride solution was added 
and the grinder assembled to give an air-tight seal in the 
sample chamber. A clean resin trap was placed in-line for 
collection, and the nitrogen gas flow was adjusted tb 20 ml 
per minute. The sample and the 2% chloride solution were 
ground together and the haloforms were bubbled out of 
solution and onto the trap. After collection, the trap was 
assembled on the thermal desorption probe, Figure II-4. The 
desorption unit was connected to the gas chromatograph and 
carrier gas- was used to flush the probe free of air. 
Finally, the probe was inserted fully into the heater chamber 
to thermally strip the haloforms from the resin onto the GC 
column, 
Gas chromatography 
All the present work was done using a 2 m x 5 mm 
glass column and Supelco, Inc., 0.2% Carbowax 1500 on 
80/100 .mesh CarbopaJBl column packing . 1 Ultrapure 
1 . 
All column supports were obtained from Supelco, Inc., 
Bellefonte, PA, 
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nitrogen from Matheson1 was used at a flow rate of 
40 ml/min for the GC carrier gas. The GC injector 
temperature was 250°C and the electron capture detector 
was maintained at 260°C, The column oven was operated at 
110°C in most cases. Overnight conditioning of the column 
was accomplished at 145°C, 
HamiltorfID glass syringes 2 were used throughout this 
study for GC injection, 
A 1 millivolt strip chart recorder was used to record 
chromatograms. 
1Matheson Scientific, Chicago, IL, 
2Hamilton Company, Reno, NV. 
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RESULTS 
Liquid-Liquid Extraction - Primary Method 
General 
Figure II-4 illustrates a typical gas chromatographic 
separation of bromodichloromethane and various related 
compounds, with almost complete baseline resolution of the 
components from each other. Carbon tetrabromide, which was 
not illustrated in the figure, eluted at about 90 minutes. 
The peaks represented 0.1 to 0.6 nanograms of haloform 
injected, depending on the compound. 
Figure Il-5 illustrates the usable sensit~vity and 
excellent linearity over a wide concentration ran~e obtained 
with the described techniques. 
Blood 
Blood was collected in heparinized Vacutainers® and 
stored at -10°C for· later analysis, Studies ·were 
initiated to determine the effects, if any, of long-term 
storage on blood levels of haloforms under refrigeration 
and freezing storage conditions. 
A large pooled collection of blood was sampled, sealed, 
refrigerated overnight, then sampled again. Table II-1 
presents the data, which illustrated the rapid loss of the 
haioform from the stored blood. 
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a - Chloroform 
methylene chloride c . 
b - Impurity 
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c - Carbon tetrachloride 
. d - Bromodichloromethane 
. e - Dichloroethane 
. f - Dibromoethane 
a 
g - Bromoform . 
d 
. 
. 
. 
. 
f 
b . g 
r 
. e 
. 
'' 
-....- -
0 3 6 9 12 15 18 21 24 27 30 33 36 39 42 
Retention Time in Minutes 
Figure II-4. Gas chromatographic separation of haloforms 
2 m glass column, 0.2% Carbowax 1500 on 
100/120 Carbopak., Supelco, Inc.; column temperature: 
100°C, injector port and E.C. detector 285°c; carrier 
gas = 40 ml/min Matheson nitrogen; amounts injected 
ranged from 0.1 to 0.6 ng of compound 
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.µ : 
Q) 
i::i 
o 0.1 0.2 0.3 o.4 0.5 o.6 0.7 o.8 0.9 i.o 
Nanograms of bromodichloromethane injected 
Figure II-5. Standard curve of bromodichloromethane 
2 m glass column, 0.2% Carbowax 1500 
100/120 Carbopak, Supelcor Inc.; column 
temperature l·00°C, injector port and E.C. 
detector 285°C; carrier gas 40 ml/min 
Matheson nitrogen 
Table 
Cone. 
Level 
1 
Cone. 
Level 
2 
Cone. 
Level 
3 
II-1. 
Trial 
1 
2 
3 
1 
2 
3 
1 
2 
3 
# 
Effects of 
First 
day 
cone. 
(ppm) 
0.087 
0.083 
0.081 
0.370 
0.360 
0,350 
2.44 
2.12 
2.13 
refrigeration 
Average 
(ppm) 
0.084 
storage on BrC1 2CH levels 
Second 
day 
cone. 
(ppm) 
0.077 
0.082 
0.169 
0.160 
1.21 
1. 22 
Average 
(ppm) 
0.079 
0.165 
1.21 
in blood 
% Change 
-6% 
-54% 
-53% 
0\ 
0\ 
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Table II-2 presents data of pooled blood sampled at 
various t.imes indicating that -10°C is a suitable storage 
method for blood up to at least 228 hrs. 
The extraction method was tested using hexane, pentane, 
and heptane, using different ratios of blood to solvent, and 
(ii\ 1 
using a surfactant, TX-lOcr', to completely hemolyze the red 
blood cells. Pentane was chosen as the extracting solvent at 
a ratio of 1 m~ blood to 8 ml pentane. Bromodichloromethane 
was added to blood at a level of 0,1 ppm with recoveries 
~veraging 94% and a range of values from 85% to 107%, Table 
II-3. Blood levels of bromodichloromethane ranged from no 
detect.able amount (NDA} in the lowest dose groups and c.ontrol 
group to 482 ppm in some of the highest dose rats, Table 
II-4, No inte~ferences or other peaks were observed in blood 
extract analysis from these feeding studies. 
Liver, kidney, and brain Tissues were stored.in 
aluminum foil at -10°C until analysis. 
Studies were initiated to determine the effects, if any, 
of long-term stora~e at freezing temperatures on tissue 
levels. Levels _did not change after 4 months of storage at 
-10°C. However, levels in samples tested after 11 months had 
decreaseci by 60 to 80% of original levels. 
1 
Triton X-100, Rohm and Haas Co., Philadelphia, PA. 
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Table II-2. Effects of freezer storage on BrC12CH levels in blood 
Hours storage 
at -10°C 12 36 60 228 
Concentration 4.48 4.10 4.20 4.11 
in ppm 4.00 4.40 4.70 4.70 
3.90 4.40 4.50 
Average, - 4.13 4.30 4.40 4.40 x 
% Change in 
concentration 0 4.1 6.5 6.5 
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Table II-3. Recoveries of bromodichloromethane from 
biological matrices 
Matrix 
Trials % Blood Liver Kidney Brain 
93 102 86 78 
103 85 101 71 
92 1.07 87 102 
85 105 101 104 
92 95 78 107 
10} 94 101 95 
89 110 72 75 
97 112 78 86 
99 83 88 
91 
89 
Average, - 94 99 88 x 90 
Standard 
deviation 7 ll 11 14 
Relative 
standard 
deviation 7 11 12 16. 
Range 85-107 83-112 72-101 71-107 
Table II-4. Blood levels of bromodichloromethane 
(blood concentration ppm) 
Dose Level mg/kg 
0 100 300 800 900 
P-0-2 NDA P-1-2 NDA P-3-1 NDA L-8-6 .03 P-9-1 .02 
P-3-2 NDA L-8-9 NDA P-9-3 .07 
P-0-3 NDA P-1-3 NDA P-3-3 .03 L-8-10 .03 P-9-4 .06 
P-1-4 .04 P-3-4 .05 L-8··17 NDA P-9-6 .04 
P-0-4 .04 P-3-6 . 04 
P-1-5 .02 
P-1-6 .06 
1600 
L-16-1 NDA 
L-16-3 .04 
L-16-4 NDA 
L-16-6 NDA 
L-16-8 .07 
L-16-14 .02 
.1-16-16 
314.2 
L-16-17 
aAnimal tatto coding is illustrated by an example from 
both the prescreen and LD 50 groups. 
P-0-2 represents number 2 rat in the 0 dose 
control group in the prescreen study. 
L-8-6 represents number 6 rat in the 800 mg/kg 
dose group in the LD 50 study. 
.11 
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2700 3200 6400 8100 
P-27-1 . 07 L-32-2 176.7 L-64-1 391.7 P-81-5 272.0 
P-27-3 108.8 L-32-5 482.7 L-64-5 280.0 P-81-15 338.0 
P-27-5 215.1 L-32.6 216.1 L-64-10 406.8 
P-27-6 .09 L-32-12 241. 7 L-64-14 403.0 
L-32-16 349.3 L-64-18 313.6 
L-32-19 414.4 
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The recovery method was evaluated by adding bromodi-
chloromethane to pooled samples of brain, liver and kidney. 
Table II-3 summarizes the recovery data for all three 
tissues and blood in detail. Liver recoveries averaged 
99.2% with a range of 83% to 110%. Kidney recoveries 
averaged 88.0% with a range of 72% to 101%. Brain 
recoveries averaged 90.0% with a range of 71% to 107%. 
No interferences were observed in the chromatograms of 
liver or kidney extracts and column integrity, as well as 
electron capture detector sensitivity did not seem affected 
by numerous injections, over an 8 hour period. 
Extractions of brain samples did, however, coextract 
some interfering compounds which affected both column life 
and detector sensitivity after only a few injections. 
Extracts were redried over additional sodium sulfate to 
eliminate water as the problem with little improvement. The 
brain extracts were observed to be slightly cloudy compared 
to liver, kidney and blood extracts. Filtering with glass-
fiber filter paper did not remove the cloudiness 
problem. Centrifugation was tried and worked very well. 
Centrifuging the brain extracts at 680 x g for 10 minutes 
cleared the extract and eliminated most of the problems 
experienced in the GC analysis. Detector sensitivity 
was still slightly affected by numerous injections over a 
5 to 6 hour period. Standards were injected regularly 
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to monitor the detector sensitivity over long periods of 
time. 
Tissue levels of bromodichloromethane ranged from NDA 
in many of the control group rats and lowest dose level 
groups to over 1000 ppm in tissues of a few rats in the 
highest 2 dos.e level groups, Table II-5. 
Gas stripping with collection 
Figure II-6 illustrates the results of the work with 
resin collection and subsequent thermal desorption into 
the GC injection port. 
Limited modifications to both the desorption unit 
and the manner in which it connects to the Packard GC 
failed to improve the chromatographic separation of a 
mixture of the haloforms, 
Figure. II-6 also illustrates the lack of sensitivity 
due to band broadening, The amounts of the individual 
haloforms injected ranged from 0.1 to 0.6 µg of compound. 
Table II-5. Representative tissue bromodichloromethane levels 
Dose, mg/kg 
0 100 800 1600 3200 6400 
Brain, ppm 0.27 1.1 233.0 112.8 772.7 238.6 
0 .16 . 0.1 8.3 0.8 146.7 57.0 
0.07 0.4 7.1 43.7 21.7 74.3 
0.26 1.4 5.3 
Liver, ppm 0.18 0.81 246.7 632.8 1201.7 1279.0 
0.53 0.05 1.1 734.4 762.0 1947.0 ___, 
0.03 0.15 2.8 o.8 737.5 838.0 -"' 
0.14 0.3 85.7 1512.5 
o.8 
Kidney, ppm 2.07 38.1 44.3 294.5 153.8 316.0 
4.3 0.87 126. 4 2.3 762.0 109.6 
2.9 1. 24 9.1 59.3 160.3 126.3 
0. 75 2.2 2.9 10.2. 7 
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a Chloroform 
b Impurity 
c Carbon tetrachloride 
a c d Bromodichloromethane 
e Dichloroethane 
f Dibromoethane 
g Bromoform 
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Figure II-p. Gas chromatographic separation of haloforms 
using thermal desorption introduction to the 
gas chromatograph 
GC Conditions: 2 m glass column,, 0. 2% Carbowax 1500 on 
100/200 Carbopack, Supelco, Inc. 
Column Temp = 100°C, injector port and E.C. detector = 285 
detector = 285°C 
Carrier Gas = 40 ml/min nitrogen, Matheson 
Haloform amounts injected range from 0.1 to 0.6 µg 
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DISCUSSION 
The present work was approached in two ways, For 
large numbers of samples at levels greater than 20 parts-
per billion (ppb), the advantages of a single liquid-liquid 
extraction were numerous, No elaborate instrumentation, 
aside from the normal gas chromatographic equipment, was 
necessary. Sample preparation was speedy and was kept to 
a minimum, and normal use of the GC was possible. 
If levels were very low, then the use of gas-stripping 
with collection and concentration was used to advantage. 
This approach offered the advantage of lower detection 
limits and freedom from many possible interferences 
experienced with the simpler liquid extraction. However, 
the assembled equipment was subject to contamination, 
interfered with the normal use of the gas chromatograph, 
and was much less efficient or speedy to work with for 
large numbers of samples, Also, the initial results 
indicated that the design of the thermal desorption unit 
and its connection to existing chromatographic equip-
ment allowed too much dead space resulting in excessive 
chromatographic b.and broadening. Figure II-6 illustrates 
the chromatogram of the haloform mixture introduced via the 
desorption unit. Although the chromatogram resembled the 
one obtained with normal injection techniques in order of 
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compound elution, the sensitivity and compound resolutions 
were entirely unacceptable. 
Modification of the hardware and perfection of the 
extracting methodology are goals of future subacute work 
with the haloform compounds. 
The pentane liquid-liquid extraction of bromodi-
chloromethane from blood, liver, kidney and brain was very 
appropriate for levels encountered in this study. The 
method presented was relatively free of interferences, very 
rapid, and complete as supported by recoveries of added 
bromodichloromethane. 
The GC determination of bromodichloromethane in 
pentane extracts of blood, liver, kidney and brain was both 
selective in its ability to differentiate the various halo-
forms from each other and sensitive in its ability to 
analyze subnanogram amounts of the haloforms, 
Impurities noted in a few chromatograms led to investi-
gation of solvent purity. Solvent purity was checked by gas 
chromatography prior to use. Solvents absorbed fumes and 
vapors from laboratory environments even when tightly capped. 
Many of the impurities were removed by adsorption column 
chromatography using activated basic alumina or silica. 
Figure II-7 shows solvent contamination and the effects of a 
single elution through a basic alumina chromatography column. 
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Figure II~7. Alumina chromatography of pentane 
A shows impurity peaks in pentane solvent; B illustrates the effectiveness 
of single pass through an alumina chromatograph column in removing them 
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All glassware was thoroughly washed in hot, soapy water, 
rinsed three times with double distilled water or equivalent 
(Millipore Milli-&fi> 1 deionized water) and fired at 500°C 
overnight in a muffle oven. 
Bromod~chloromethane is very volatile with a boiling 
point of 87°C. Obvious problems of haloform loss with 
evaporation of solvent to gas headspace or into the 
laboratory environment when containers are unstoppered must 
be recognized and avoided when possible. 
No long-term storage conditions were found. Freezing 
the tissues and blood at -10°C was adequate for short 
periods of time, blood at least 9 days, and tissues at least 
4 months. 
For blood extractions, pentane was chosen because it 
produced a better chromatographic separation from the early 
eluting haloforms than did hexane or heptane. TX-lOO<!l)was 
also investigated because of its hemolyzing properties on 
red blood cells. In most cases, a ratio of 1 ml blood to 
4 ml pentane was less clearly divided even after centri-
fugation. In every case, the addition of any TX-lOOR to the 
blood followed by pentane extraction produced a solid 
proteineous plug which could not be separated by filtration 
or centrifugation into the biphase layers. 
1Millipore, Bedford, MA. 
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However, ·reextractions and spike addition studies 
indicated that a pentane extraction was successfully 
removing the blood haloforms produced by dosing animals 
with bromodfchloromethane, Table II-3. Pentane also proved 
to be superior to hexane and heptane for the extraction of 
the tissues because of better GC separation. 
Blood levels fell into two 2 groups, Tab1e II-4. 
Animals surviving through the 2 week study generally had 
blood levels of 100 ppb or less. Animals which died during 
the trials generally had .much higher blood concentrations, 
often in the hundreds of ppm, The level in these latter 
animals reflected both the dose level received and the 
length of time they survived. The larger doses resulted in 
higher blood concentrations. The longer.·living animals 
generally had lower blood levels due to elimination, 
metabolism; or compartmentation into other tissues. 
Tissue levels of the dosed animals reflected both the 
initial dose received and the length of time the animal 
sur.vived, Tabl.e II-5. As with the bloo.d levels, the ti.ssue 
levels were very low or at the control levels if the animal 
survived the 2 week observation period. Animals dying sooner 
had much higher levels, Table II-5. Measurabli: levels of 
bromodi.chloromethane in the control group were thought to be 
due to·inhalation.~y the control group of exhaled bromodi-
Chlorocietha~e £rom the bther dose groups. Further studies 
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involving the chro.nic toxicity of the haloforms should 
consider this source of cross-contamination and separate 
cages in well-ventilated areas. 
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SUMMARY 
The proposed liquid extraction methodology provided 
quantitative extraction of bromodichloromethane from 
blood, liver, kidney and brain at ppb concentration 
levels. Interferences were noted in some brain tissues 
but centrifugation largely solved the problem. The 
chromatographic conditions used produced well-resolved 
chromatograms of bromodichloromethane and other haloforms. 
Storage at -10°0 was found to be adequate for storage 
periods of 4 months or less. Tissue levels in the various 
matrices reflected both the dose level received and the 
length of time the animal survived. 
The proposed gas-stripping with thermal desorption 
methodology resulted in unacceptable GC separation due 
to bas.ic equipment design and methods available for 
connecting the equipment to the gas chromatograph. 
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SUGGESTIONS FOR FUTURE WORK 
Future work could better define the effects of exposure 
to bromodichloromethane on blood chemistry values, 
Also, using data from the present work, a subacute 
toxicity study could investigate low level longer term 
effects of haloform exposure. 
Modification and refinement of the trap-and-purge 
concept should be areas of future work as well. 
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APPENDIX 
Classical LD 50 Determination 
The method of Litchfield, 1949, is considered a 
standard in the field of toxicity determination. The method 
is relatively fast, straightforward and easily used. Its 
accuracy increases as the number of groups which have some 
mortality but not all, increases. 
# Dead/total % Mortality % Mortality % Mortality 
tested Corrected Expected 
0 0/7 0 
400 0/9 0 1 3.2 
800 2/9 22.22 16.5 
1600 3/9 33,33 46.o 
3200 7/9 77,78 81. 0 
6400 919 100.0 99 93.0 
(X) 2 test for lihe ho~ogeneity 
Expected - Observ~d (or corrected) =contribution to (X) 2 
3,2 - l" = 2.2 = 0.16 
16 .. 5 = 22.22 = - 5.72 = .025 
46 - 33,33 = 12,67 - .065 
81 - 77.78 = 3.22 = .0061 
93 - 9.9 = 6 = .034 
.146 
9la 
Average # of animals/group = 8.67 
(X)2 2.146 x 8.67 = 1. 283 df = 3 
(X)2 = 1.283 less than p (.05) of 7,82 
Therefore, graphed line is a good fit of data. The 
LD50 can be read directly from the graph 
LD16 = 800 mg/kg 
LD50 = 1740 mg/kg 
LD54 = 3900 mg/kg 
Calculation of CI for LD50 
3900 + 1740 
s = 1740 800 = 2.208 
2 
N = 27 
So, f = s 2.208/"N = 1. 52 
LD5.0 
upper CI = 1. 52 x LD5 0 = 2644.5 at p (.05) 
upper CI = LD50 x 1. 52 = 1740 
9lb 
SAS, ANOVA, GLM, and PROBIT Procedure1 
1Barr, Goodnight, Sall and Helwig, SAS Institute, 
Inc., P. O. Box 10066, Raleigh, NC 27605) 
I 
. I 
ITERATION 
COVARIANCE MATRIX 
INTERCEPT 
SLOPE 
0 
z 
3 
• 
5 
INTERCEPT 
0.19666568 
-0.00009113 
CHI-SQ 
LOSO MALES FINAL 13:46 MONDAYo OECEMBE~ 3• 1979 
PROBlT ANALYSIS ON DOSE 
INTERC:»T 
4.60504348 
.3~65605281 
3.34006617 
.3. 29984<;;61 
J.29922477 
J. 29922462 
SLOPE 
-0.00009113 
0.00000007 
5.J447 WITH 
SLOPE 
0·00050047 
0.00085544 
0.00101934 
o.COl04097 
a.00104131 
0000104132 
4 OF 
MU 
779.82071502 
1571.06287129 
1628.44596346 
1633. 23°498908 
1633.29574201 
1633.29575381 
SIGMA 
1974.446i;7676 
1168·99152540 
98i.03004894 
961)064148381 
960·32427839 
960·32420039. 
COVARIANCE MATRIX 
MU 
SIGM~ 
PRC6 > CHI-SO 
MU 
78149.12856839 
20016.23005504 
SIGMA 
20016.23005504 
5922l o61J90951 
NOTE: SINC: THE CHI-SQUARE IS SMALL (P > 0-101 0 FIDUCIAL LIMITS •ILL BE CGMPUTEO USING AT VALUE GF t.i;6 • 
LOSO MALES FINAL 
DBS DOSE N MORT 
0 • 0 z 400 10 0 
3 aoo 4 z 
• 1600 6 • s 3200 9 • 6 64!JO 9 9 
z 
PROBIT 
10 • 
•• 
• • 
7 + 
• • 
s + 
• + 
3 • 
I 
I 
I 
2 + .. 
I ·+ 
0 + 
x 
x x 
LOSO MALES FINAL 13!46 MONOAYo DECEMBER 3o 1979 3 
P'ROBIT ANALYSIS ON DOSE 
.x 
x 
x 
------------_+---------------+---------+-----~---+---------~·--------+-------------~--·-------------------------~---------------
LOOl LOlO L025 LOSO LD75 L090 LO<;i9 
-600.752 402:.591 9d5o567 16~3.2~6 22810025 2864.001 3867.344 DOSE 
PROBABILITY 
1.0 + 
0.9 + 
0.0 + 
0.7 + 
I 
I 
I 
0.6 + 
o.s + 
0.3 + 
0.2 + 
0.1 + 
o.o + •••••••••••• x 
LOSO NALE5 FINAL 13!46 MONDAY, OECEMBCA Jo 1979 • 
PRCBIT ANALYSIS ON DOSE 
••••••••••••••••• : •••••••••••••••••••••••• x 
x 
x 
x 
------------+---------------+---------+---------+--------~+--------+----------------·----------------------------~-----------
LOOl LOlO L025 LOSO L075 L090 L099 
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LOSO NA.Li::S FJN4L 
PROBIT ANALYSIS ON DOSE 
PROBABILITY DOSE 95 PERCENT 
LOWER 
0.01 -60:).75240444 -Z622.l540<;'i93 
0. 'o2 -338.96902332 -2121.2.3090552 
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0.04 -47.93044_491 -1571.l56877S.1 
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a.as 2628.60781'317 200lo8'i865887 
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o.9i 29.20 .• ass2s131 2226.5:5715781 
0.92 2982.61997421 2272-97200602 
0.93 3050.S:J3590SJ' 2323.65813828 
o. 94 3126. ::6246035 2379-87243740 
o·.95 3212.88849524 2443.52668601 
o •. 96 ,33,1~. 5219525<! 2517. 75517986 
0.97 3439.46736865 2608.28586197 
o.98 360:t. 56053 093 2,727.57444176 
0.99 3867.34391205 2913-60180170 
13:4~ MONOAYo DECEMBER 3o 1979 
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P"ce > CHI-SC 
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SIGMA 
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NOTE: SINC~ THC CHI-SauAhE IS SMALL (P > o.lOJ. FIDUCIAL LIMITS WILL BE CCM?UTED USING A T VALUE OF 1.96 • 
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x 
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2 ... 
l + 
0 • x x 
----------+----~-------+---------------+--------+-----------+--------+-------------~------------------~------------------------
LOOl 
-1eo.9e3 
LDlC 
576.22:<: 
LC50 LC7.5 
150~.ee~ 1s92.121 
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DOSE 
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PROBABILITY PRCBIT ANALYSIS ON DCSE 
x •••••••••••••••••••••••••••••••••••••••••••••••••••••••• x 
o.a + 
••• 
x 
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x 
0. 2 + 
0 .1 + 
o.o ••••••••••• x x 
----------+------------+---------------+-------~+-----------+--------·---------------------------------------------------------
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PROBABILITY DOSE 95 FERCENT 
LOWER 
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0.01 43:5.62008507 -1oc;;.c1a49451 
o.oa 486.a1102c:od -597.25678769 
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0 .::.s l<:so.1ooec;e27 902.71378209 
0.40 1::!63.S1c;22c;c;5 102c;.:;:44~c;4c;7 
0 .. 45 1473.252'>l7386 1145.C07448585 
o .. so l SC!l. 24693071 1255.53827233 
o .. 55 1669 .·24oee 756 13€0.:06.::ee-13 
0.60 1798.97463147 1463 .. 11190930 
0.65 l'il2.3931E515 l565.5e472C72 
o. 70 2031.c;1921se<,;. 1670.24€452<;3 
o. 75 2lt:O.SOE61770 1780.16580040 
o .. ao 2304.!:4020!:37 1899.6665€400 
o.85 2471.C0626'i618 2035.9097444.3 
0.90 2682.Cl6418C3 2203.88090562 
0.91 2733.49815<;06 224:!.c;<;345251 
0.92 2 788. 77208577 2267.40471620 
O .. <;::! 2849-54873252 233 4. 'i4 7<i23 l 0 
0.94 2917.42672431 2:;a1.e3401eo1 
0.95 2994. e4193oc;1 2447.90354748 
0.96 3oe5. 79483496 .zsl'e. l 75eoe2s 
0.<;7 3197.60986861 2604.17330543 
0 .. 98 334C..Z4847501 271,7.<;157Z253 
0.99 3560.52131572 29c;;e .. oc;asao59 
13:52 TUESCAY• NCVEMeER 13 • 1979 
FIDUCIAL LIMITS 
UPPER 
105.62f5!j024 
2B9.49f:0;;:42B 
407.94736621 
498.24<:34804 
572.604159\)2 
636 .. E5e403ee 
693.47362283 
744.93ES5211 
792. 2 7C007422 
836 .. 35933267 
102s.oses2eo1 
1184-13720715 
1328.94'i8'>l8C3 
1466-76425399 
1601.6'531492S: 
17JE.22'i33303 
1672 .. 31036247 
2011.45095653 
215s.1e722466 
2305-2<;272439 
2464.041560961 
2634.61726349 
2821. 7<:90942:! 
303J.02e90413 
3282.:!Soseoc;o 
3599.50€72839 
3676.5€753<;5!: 
3760.4;121394 
3652.87!:41432 
3<;;56-~0€69180 
4074.52035702 
4213. 7~ 7835Q6 
4385.21445720 
4613.7788<;525 
4'>l75.ll403404 
5 
f--' 
0 
w 
LOSO TOTAL POPULATION, SCF:E:::N Af'!O FINAL CO·'IBINEC PRCC PF<.CBIT LN 2 
1:!~2e FG:IOAY, NOVE~eEP. 16. 1'779 
PF:CBIT ~NALVSIS ON OCSE 
ITERATION 
COVA~IANCE MATRIX 
I NTEPCEPT 
SLOPE 
0 
2 
• 
INTERC;:.PT 
o.09278360 
-'l.OO'J044S5 
CHI-SQ 
.3.68G59'1S6 
3·26'i00l49 
3.21s2ee74 
J.2f4.J914e 
3.214.J.;;122 
SLCPE 
-0.00004495 
0.00000003 
~.6061 ,WITH 
SLCP::: 
o .. oooao911 
0.00101702 
0.oo194f:40 
0.001046<;2 
o.o0Io4oc;2 
d OF 
•u 
1630 .. e~5.,,,,210 
17,J2. C2f:22955 
110:>.:744te77 
1705 .5812S5f:,J 
1705.:81::!~!91 
S IG."'.1 
'1235,.924E4C.21 
9s::.2e2c1r;1a 
955.~57:;<;242 
95S.1S~O<;t;;4 
95; .181 '75461 
CCVA~IANCE M4TRIX 
NU 
SIGMA 
PROB > CHI-SQ 
NU 
291J7.472463i;o 
aoe~.15c;4.::;32s 
0-:!7f:6 
"ICTE: SINCE THE CHI-30UARE IS SMALL (p > O.tol·, FIDUCIAL Ll."llT.S WILL SE CClolPUTEC USING fl T VALUE CF l .. 9f:,. 
CBS oosc: N liCCRT 
1 100 6 0 
2 :?00 6 0 
3 "' 1 a 0 • 800 1:; 5 
5 9JC ' 6 1e:io 1 5 B 
7 2700 • • 8 .32.00 18 17 
9 6400 1. 10 
10 81'00 • 6 
SIGM4. 
aoae.1:s.is32:; 
26468.E2!:~77:;13 
Loso TCTAL PCPULATlON. SCREEN A~~ FlNAL C~M8I~ED PRCC PROe 1 T LN 3 
1.:::2e FQlCAY. r.icvev3ei:t 16. 1979 
::>RQBlT PRCSIT ~NALYSIS CN DOSE 
10 • 
• • 
• • 
7 • 
..x 
•• 
x 
5 • J( ••• 
x 
• • ••• x 
J • 
2 + .. 
I ' 
0 • x xx 
------------------+------------+--------+---------------+-------------+--------------------------------------------------------
LOO:;: L025 LOSO LC90 LC'ii9 
1~4°4•·7 l06l•J2l 1705.SSl 29C9.596 ::927.667 OOSC 
f-' 
0 
Vl 
LOSO TOTAL POP 1JLATION, SChEEN ANO Flt.AL C0"4.9INEO 
PhOBABILITY PRO~IT AN~LYSIS CN ocse 
J.,, • 
x •• 
0.9 + 
0 .s • 
o. 7 • 
x 
x 
o.s + 
0 .4 + 
x 
0.:? + 
0.2 + 
•• x 
0 .1 + 
x " 
?R~C PRC!BlT LN 4 
JJ:2e FRIDAY, f\CVEWB2R 16, 1979 
• ••••••••••••••••••••••••••••••••• x •••••••••••••••••••••• x 
I-' 
0 
0\ 
------------------+------------·--------+---------------+-------------+---------·-----------------------------------------------
LOOS 
134.447 
L025 LOSO 
1061.321 t7o;.sat 
L0'9"0 
~927.667 COSE 
---------------------
LOSO TOTAL POPULATIONo SCREEN AND FINAL COMBIN~D P~UC Pi:<CEIT Lh 5 
13:28 FRIDAY, hCVE~95H 15• 1979 
PROBIT ANALYSIS ON CCSE 
PROBABILITY OCSE 95 PE~CENT FICUCIAL LI.14ITS 
L~•E"1 Ul=PE:i-0 
o. 01 -516. 50422~94 -1 SS'i .J<;52t;6S 7 42. IC7Jll-i:; 
0.02 -256.122Cl3Ea -1178. 'ieJ:.!o7::2 ia47.1:!1C462.37 
o.o:! -90.91863007 -939.11310810 379.31595531 
0.04 33.35754112 -159.a·aa213 .. 9 400.11c;;1c10:: 
.J. OS 134. 4467s1c;o -614.5113'il20 se2.47oe;4::;c;;sc 
0 .. 06 220.43960:!20 -491.sa.a.2::4e2 CJ!.2201Sl49 
0 .. 01 295.<;32325.24 -384.3524C6:!4 ec;s.201:i.:io;s2 
o.oa 363 .4a2<aS468 -2se. e::a44631 1s2. 3::212s1 a 
o.oc; 424.9162701<; -202o428242'i6 804 .2cc9a-:;.~ 1 
0.10 ~8t.46t-3:452 -12.?.::12s::e1s 852. 371201·01 
0.15 715.598912!>5 198.9571()129 1CS7 • .:>c;<;577¢5 
0.20 901.67986822 447ol77571f.1 12?.7.72'JC0347 
0. 25 1 061. 32084493 552.e::1:1e::; 1381 .;11046<;3 
0.30 1204. 5833 7592 S29-'i3867209 1s2-:: • .;1e::::o29 
cJ,.35 1:!::7.5Jo12e1a c;01.21oc;;ee::; 1668-7227.3534 
0.40 1463.58671)105 1120:0.111eo122 ieoc;.i;o104-'2.2 
0.45 1sas.ss1e3111 12El 045862538 1952.7256'7003 
0.50 17os • .:a1ze101 1385.37115871 209a.so;21c;s63 
o. 55 1825.610732'30 1504.1230!:224 22S0.40'i13104 
0-60 1947.5738C256 1621l.171C0547 24oe.ee1es11.s 
a.cs 2073.!:324374<:. 17J5.S725754~ 2576.e20.;ces1 
0.70 2206.4791a769 1854-24725479 21s1.se .. 4~:;;51 
0.75 2349.E4171!C.9 1979.3'i'3ClE:76 2o;se.1oe2c;31~ 
o.a"J 250Q.402t:<;.:=o; 2113o279430S2 3190.S4<;1·12C8 
o.0s 2E9S.563750<;6 2267.084101615 34~5.:!!531:?78 
0-90 2929. E<;6.<:..J<;Oo; 24SC.75,)1982l 3782.<;17:!5760 
I). 91 298b. 2462<;342 2S0.2.056B4374 3E!:4.E't72194::! 
0 .. 92 3047.!:80278<;;3 2ss1. oc;ozsa:::.; 3<i54-l427715-i 
0.93 3115.2302:?937 2504.eoo1eoe2 "\052.. 411c;a4,;.e 
0.94 3190.67295041 2664.SS4d6711 4162.533874<;0 
0.95 3276.71578165 2732.4372S343 4288-3213.;63<; 
0.96 3377.80502249 2a11.eesu4c;35 44315.431'77478 
0.97 .Jsoz. 091 :?93e9 z9oc;.oe;;.:;:14s 4fol6.c;:;45oc;od 
U.98 36!:7. 2851 772.9 3CJ7. 71752_3E4 486::!. t seozc;;c;;e 
0.99 3927.66676755 .32J<;.;cc;a.s4.;e1 5246.~~H:14c;;u2 
S T A T I S T I C A L 
OBS 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 ,, 
34 
3S 
36 
37 
38 
39 
40 .. 
42 
43 
44 
45 
46 
47 
4S 
49 
so 
51 
52 
53 
54 
DOSE 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
4 
• 
4 
4 
4 
4 
• 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
8 
8 
• • • • 
8 
8 
8 
8 
8 
8 
8 
8 
l. 
16 
16 
lE 
16 
16 
16 
16 
AN 
4 
s 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
1 
3 
4 
5 
6 
7 
• 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
1 
2 
3 
4 
s 
6 
7 
• 
9 
10 
15 
16 
17 .. 
l 
2 
3 
4 
5 
6 
7 
• 
SEX 
2 
2 
2 
2 
2 
2 
2 
l 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
l 
l 
1 
2 
2 
2 
2 
2 
2 
2 
2 
ANALYSIS 
... 
234 
238 
244 
270 
247 
284 
433 
421 
410 
407 
425 
46~ 
444 
405 
266 
236 
257 
260 
289 
236 
250 
280 
'22 
402 
404 
418 
4S2 
412 
406 
470 
386 
243 
259 
255 
2S4 
271 
29J 
270 
24S 
260 
396 
436 
386 
431 
390 
258 
238 
271 
258 
259 
281 
255 
249 
HTO 
336 
336 
336 
336 
336 
336 
336 
336 
:?36 
336 
336 
336 
J36 
336 
336 
336 
336 
J36 
336 
336 
336 
336 
336 
3J6 
336 
336 
336 
336 
336 
336 
~36 
336 
336 
336 
336 
336 
84 
336 
84 
24 
336 
336 
84 
12 
336 
7 
84 
120 
336 
336 
84 
336 
7 
J36 
S Y S T E N 
RHTD 
0.002976 
0.002976 
0.002<;71: 
0.002<;76 
o.00297f: 
o.00297f; 
0.002971: 
0.002976 
o.002c;7f; 
0.002976 
o.002c;7f: 
00002976 
o.09297f: 
0.002976 
0.002976 
0.002<;76 
o.oozc;7f: 
Oo00297E 
0.002976 
0.002<;76 
0.002976 
Oo002<;7f; 
Oo00297f: 
0.002976 
o.002<;17E 
0 o00297f; 
0.002971!: 
0.002976 
0.002976 
o.oozc;7f: 
0.002976 
Oo00297E 
0.002"il7f; 
0.002976 
0.002976 
0.002976 
0.011905 
0.002'<76 
0.011905 
0.041667 
o.oozq1t 
0.00297f; 
o.011c;o' 
o.oeJJJ:! 
0.002976 
o.142es7 
0.01190'5 
0.0093:!:! 
00002976 
0.00297f; 
o.011c;os 
0.002976 
o.142es1 
OoOOZ97f; 
s 
1 
l 
1 
1 
l 
1 
l 
1 
0 
0 
0 
0 
0 
0 
0 
0 
l 
0 
l 
0 
1 
13!30 NONOAYo NCVS:NBER 121 1979 
I-' 
0 
00 
ST AT IS T I.CAL 
OBS 
SS 
S6 
57 
58. 
59 
60 
61 
62 
63 
6• 
65 
66 
67 
68 
69 
70 
71 
72 
73 
7• 
75 
76 
77 
76 
79 
ao 
Bl 
82 
83 
64 
65 
66 
67 
68 
89 
90 
91 
92 
93 
9• 
95 
96 
97 
96 
.99 
100 
DOSE 
16 
16 
i6 
16 
16 
16 
16 
16 
16 
16 
32 
32 
32 
32 
32 
32 
32 
3< ,. 
32 
32 
32 
32 
32 
32 
32 
32 
32 
6• 
64 
6• 
64 
6• 
64 
6• 
64 
64 
64 
64 
64 
64 
64 
64 
64 
64 
64 
AN 
9 
to 
lt 
12 
13 .. 
15 
16 
t7 
18 
l 
2 
3 
• 
5 
6 
7 
• 
9 
10 
lt 
12 
13 .. 
15 
16 
17 
18 
l 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 ., .. 
15 
16 
17 
•• 
SEX 
2 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
l 
1 
l 
1 
2 
2 
2 
2 
2 
2 
2 
2 
2 
l 
1 
l 
1 
1 
ANALYSIS 
WT 
26i 
379 
386 
385 
308 
430 
427 
411 
3S5 
350 
2S5 
242 
235 
260 
287 
279 
247 
272 
264 
363 
397 
417 
392 
44.3 
444 
422 
369 
366 
241 
241'. 
264 
273 
256 
235 
245 
251 
266 
384 
430 
44S 
426 
427 
380 
439 
4,74 
387 
HTO 
12 
64 
•• 
7 
64 
336 
120 
7 
336 
7 
7 
12 
12 
12 
7 
7 
31 
7 
7 
48 
7 
12 
7 
336 
96 
7 
7 
7 
7 
12 
7 
12 
7 
7 
12 
7 
7 
7 
7 
48 
7 
12 
7 
7 
7 
12 
SYSTE"4 
l<IHTD 
0.08333:! 
tJ.011905 
0.011905 
. _0.14?857 
0.011905 
o .. 002<;7t.; 
o.qoaJ33 
0.142857 
0.0029715 
0 ol42~57 
0.142857 
0.083;!33 
IJ-.083333 
o.oa333:: 
o .. 142es1 
0.142857 
o.0322se 
Oo.142857 
0.142~57 
o.02oa33 
o.1•2es1 
o.oe333;: 
0.142657 
o.002o;1t:. 
0.010417 
0.142857 
0.142657 
0.1_42857 
0.142857 
o.oeJJ.::!3 
0 .. 142657 
o.oeJJ33 
Q.142651 
o.t42!JS7 
0.083333 
0-142857 
0•142857 
0.142857 
0.142857 
0.020833 
0.142857 
o.oe3333 
0.'142857 
o.1•2es1 
o.1•2es1 
o.oeJJJ:! 
s 
0 
0 
0 
0 
0 
0 
0 
j 
0 
0 
0 
0 
0 
0 
·o 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
DOSE 
0 
• 
8 
16 
32 
•• 
S T A T 1 S T I C A L ANALYSIS 
SEX=l 
SYSTE14 13:30 MONOAYo NOVEMBER 120 1979 
GENERAL LINEAR MOOELS PROCEOU~E 
MEANS 
N s HTD J<HTO WT 
8 1.00000000 336.000000 o.00297619 426.000000 
9 1.00000000 336.000000 0.00297619 4.19.111111 
5 0.4.0000000 155.000000 0.04880<i52 4.07. 800000 
9 0.22222222 118.333333 0.053174.Eio 390.333333 
9 0.11111111 58.555556 0.09242725 4.03.666667 
9 0.00000000 12.666667 0.1160714.2 4.21.333333 
7 
f-' 
f-' 
0 
S T A T I S T I C A L ANALYSIS 
SEX=l 
S Y· S T E ~ 
GENERAL LINEAR MODELS PROCEOU~E 
LEAST SQUARES MEANS 
DOSE s HTO RHTD 
LS MEAN LSMEAN LSMEAN 
• O.t;748Sl59 3Z4.187494 0.00994787 • 0.98671235 .329. 748~8'9 0.00666St:8 
8 0.40612127 1~7.879813 0.04710987 
16 0.25831484 13~-31~4t:7 0.04315:?02 
32 a.12432484 64.772086 o.08875828 •• -0.01710080 4.621422 0.120819E9 
13:30 MONDAY. NOVEMBER 12. 1979 8 
DOSE 
0 
• 
8 
16 ,, 
64 
S T A T I S T t C A L ANALYSIS 
S€X=2 
SYSTEJ<ll 13:30 MONDAY, NOVEMBER 12• 1979 
GENERAL LINEA~ MODELS P~CCEOURE 
MEANS 
N s HTO FiHTO WT 
7 1 .. 00000000 336.000000 o.002o;76t9 252.28S714 
8 1.00000000 336.:>00000 0.00297619 259.250000 
• 0.66666667 245. 33333:3 0.00925926 261.111111 • o.44444444 183.444444 0.03002~46 25a.aaaaa9 • 0 .. 00000000 11.333333 0.11072709 260 .. 111111 • O.OOOOl'JOOO a.666667 0.123015S7 253.111111 
13 
S T A T I S T I C 4 L ANALYSIS 
SEX=2 
S 'I' S T E llC 
GENERAL LINEAR MODELS PROCEDURE 
DOSE 5 HTC i:iHTO 
LS MEAN LS MEAN LSMEAN 
0 1. 00988463 338. 423902 0.00428125 
• 0.99699755 3.35.263741 0.00257978 
B 0.66022032 243.752565 0.00840816 
16 0.44211021 182.87204t: 0.02971827 
32 -o. 00459590 l0.20€:331 0.110120~0 
•• 0.0083S:727 10.7-16031 0.12411927 
13:30 MONDAY, NOVEMBER 12t 1979 •• 
f-' 
f-' 
w 
OEPENDENT VARIABLE: WT 
SGURCE OF 
~COEL 5 
ERROR 43 
COR<:iECTEO TOTAL •• 
scu;;ice OF· 
oos:: 5 
STATISTICAL ANALYSIS 
SEX.:1 
SYSTE-.t 13:30 MONOAYo NOVEMBER 121 1979 16 
ANALYSIS OF VARIANCE PRCCEOURE 
SUN OF SQUARES MEA/'i' SOUAR:;: F VALUE PR > F R-SQUARE c.v. 
7725.69686621 1545.13977324 2.07 0.0678 
32091.t:86Seee9 746.318346C5 STD DEV llfT MEAN 
39817.~6775510 27.31882769 411.367:::!'4694 
A.NOVA SS F VALUE PR' > F 
7725-69886621 o .oe1e 
DEPENDENT VARIABLE: WT 
SCUACC DF 
MODEL 5 
EH ROA .. 
CORRECTED TOTAL so 
SC UR CE DF 
DOSE s 
STATISTICAL ANALYSIS 
SC:X=2 
SYSTE/14 13!30 MONDAY. NOVE."tBER 12. 1979 21 
ANALYSIS OF VARIANCE PROCEDURE 
SUM OF SQUARES MEAN SQUARE F VALUE PR > F A-SQUARE c.v. 
583.43744164 116.68748833 0.7983 
1122B.48412696 249.521S6o;4o; STD DEV WT MEAN 
11811.921568E3 15.79626125 257.6274501;;8 
ANOYA SS F VALUE c:IR > F 
583.43744164 0 .47 o.7c;a3 
DEPENDENT VARIABLE: HTD 
SOURCE OF 
MODEL • 
ERROR •• 
CCRRECTED TOTAL •• 
SCURCE OF 
DOSE • WT 1 
S T A T I 5 T 1 C A L ANALYSIS 
SEX=l 
SYSTEP4 
GENERAL LINEAR fl400ELS PRCCEDUAC 
5Ufl4 OF SQUARES 
B4B695.;41900858 
322972 .. 54017509 
1171567.959193l:7 
TYPE I SS 
927781 .. 736961 &5 
20913 .. 69204713 
MEAN SQUARE 
141449 .. 23650143 
F VALUE 
21 .. 54 
2.72 
PR > F 
0.0001 
o .. 1065 
F VALUE 
19.40 
OF 
s 
1 
PR > F 
0.0001 
STD DEV 
87.67805559 
TYPE IV SS 
756561.7.tt.611969 
20913.6820471.! 
5 
A-SQUARE c.v. 
o .. 7244.lO 52.4377 
HTD JICEAN 
167.20408163 
F VALUE PR > F 
I-' 
19.68 0.0001 I-' 
2.72 Q.lOl:S 0\ 
OE?ENOENT VAR IA8LE: HTO 
SOURCE OF 
MODEL 5 
ERR CR 43 
CORRECTED TOTAL •• 
SCUHCE OF 
DOSE 5 
S T A· T 1 S T I C A L A N A L 'f' S I S 
SEX=l 
SYSTEM 13:30 MONDAY. NOVEMBER 12. 1979 18 
ANALYSIS OF VARIANCE PRCCEOURS 
SUM OF SOUARC:S MEAN SOUARC: F VALUE PR > F R-SOUARE c.v. 
827781. 73696145 165556.34739229 20.71 0.0001 o. 706'559 53.4765 
343786.22222222 7<';95.02842377 STD OEV HTD MEAN 
1171567.95918367 89.41492282 167.20408163 
ANOVA SS F VALUE PR > F 
827781.73E96145 20.71 0.0001 
DEPENDENT VARIABLE! HTD 
SOURCE 
'400EL 
ERROR 
CCARECT~O TOT AL 
SCiURCE 
DOSE 
WT 
OF 
• 
•• 
50 
OF 
5 
S T A T I S T I C A L ANALYSIS 
SEX=2 
SYSTE"4 
GENERAL LINEAR ~OOELS PROC~OUPE 
SUM OF- SQUARES MEAN •SQUARE F VALUE 
925906.74943616 154317.79157269 20.8J 
326010. 23095599 7409.32343082 
13!30 MONQAYe NOVEMBER 12• 1979 11 
PR > F R-SQUARE c.v. 
0.0001 o.739s'iil 48. 3~28 
STD DEV HTO MEAN 
1251916. 980 .!9216 86.07742695 17B.Ol'ii60784 
TYPE I SS 
923594.75816993 
2.!11.9912tif:23 
F VALUE PR > F 
0.0001 
0.5793 
OF 
• 
' 
TYPE IV SS 
922254. 20927222 
2311.99126623 
F VALUE •• > F 
2•.e9 0.0001 
0 •.!I 0.!5'.793 
1--' 
1--' 
co 
OE"'ENOENT VARIABLE: HTO 
SGURCE OF 
MODEL 5 
ERROR 45 
CORRECTED TOTAL 50 
SCU"-CE OF 
DOSE 5 
S T A T I S T I C A L A ·N A L Y S I S 
SEX=2 
SYSTEl'4 13: 30 MOhDA Y • NOVEMBER 12 • 1979 
ANALYSIS OF VARIANCE PROCECURE 
SUllll OF SQUARES MEAN SQUARE F VALUE ?A > F A-SQUARE c.v. 
923594. 75816993 l 84 718· 95163399 25.32 0.0001 0.737744 
328322. 22222222 7296.04<;138272 STO OE'w' HTD MEAN 
IZS1916.980.?c;<216 8S.41E9l509 178.01960784 
ANOVA SS F VALUE PR > F 
923594. 75816993 25.32 0.0001 
DEPENDENT V.IAI.leLE: s 
SOURCE OF SUN 
NCOEL • 
=ARCA •• 
CORRECTED TOTAL •• 
SOURCE OF 
DCSE • 
WT 
STATISTICAL AN.&LTSJS 
SEX=l 
SYSTEM 
GENERAL LINEAR MODELS PAOCEDU~E 
OF SQU.IACS MS:AN SQUARE F VALUE 
8.572494::iS 1.42874906 16.90 
J.5499S4~3 0.08452273 
13!30 .,,.ONOAY• NOVEMBER 12. 1979 • 
•• > F R-SQUARE c. v. 
0.0001 0.707159 6•.7530 
STD DEV s MEAN 
12.12244898 o.29072793 o.44897959 
TYPE I SS 
8.47800454 
0 .09•48982 
F VALi.iE 
20. DIS 
1. 12 
PA > F 
0.0001 
0 .2964 
OF 
• 
TYPE IV SS F 'IA.LUE •• > F 
7.71370364 1a.2s 0.0001 
o.0944a9e2 I .12 0.2964 
f-' 
"' 0 
OE?ENOENT VAR I ABLE: RHTO 
SOURCE OF SUM 
NO DEL • 
ERROR •• 
CCAS:OECTED TOTAL •• 
SC UR CE OF 
DOSE s 
WT l 
S T A T I S T I C A L ANALYSIS 
SEX=l 
SYSTEM 
GENERAL LlhEAR MODELS PROCEOU~E 
OF SQUARES 
O.Q99649J! 
o.09277451 
0.19242386 
TYPE l SS 
O.O'i23644<; 
0 .00728486 
MEAN SQUARE. 
0.01060623 
0.00220992 
F VALUE ?R > F 
0.0001 
0.0765 
F VALUE 
OF 
s 
l 
PR > F 
0.000.1 
STD DEV 
o.o.~99911 
TYPE IV SS 
0 .08786023 
0.00728466 
• 
A-SQUARE c.v. 
0.517864 66 .t;l 38 
RHTO "'EAN 
0 .05407556 
F -VALUE PR > F I-' 
7.9.e O.OOQI "' 3 .Jo 0.0765 I-'
DEPENDENT VARIABLE: A ti TD 
SOURCE OF SUN. 
MODEL 5 
ERA CA 43 
CORAECTEO TOTAL •• 
SCURCE OF 
Dcse • 
s T A T l s T l c A L ANALYSIS 
SEJC=l 
SYSTEM 13:30 NONDAY 9 NOVEMBER 12• 1979 •• 
ANALYSIS OF VARIANCE PROCECU~E 
OF SQUARES MEAN SQUARE F VALUE PR > F R-sauA"E c. ". 
o .0923e449 o.01a•1290 7.94 0.0001 0.480005 89-2059 
0.10005937 o.002J2696 
' 
STD DEV AHTD NEAN 
o.t92423B6 o.04a2~11s9 o.os401ss6 
A NOVA SS F VALUE •• > F 
0.09236449 7.94 0.0001 
DEPENDENT VAR I.ABLE: AHTO 
SOURCE OF SUN 
lfllCDEL • 
ERROR 44 
CORRECTED TOTAL so 
SOUQCE OF 
OCSE 5 
WT 1 
S T 4 T I S T I C 4 L ANALYSIS 
SC.X=2 
SYSTEM 13:30 MONDAY. NOVEMBER 120 1979 12 
GENERAL LINEAR MODELS PROCEDURE 
OF SQUARES 
o.13:!49406 
0.04091403 
0.17440809 
TYPE t SS 
0.13282384 
0 .00067022 
MEAN SQUARE 
0·02224901 
0.00092986 
F VALUE 
28.57 
0.72 
PA > F 
0.0001 
0.4005 
F VA.LUE 
2~. 93 
OF 
5 
PR > F 
0.0001 
STD DEV 
o.03049368 
TYPE IV SS 
o.133442'i'9 
o.00067022 
:;!-SQUARE 
0.765412 
F VALUE 
2e.7o 
0 .72 
c.v. 
RHTO MEAN 
0.04905686 
PA > F 
0.0001 
0.4005 
,__. 
f\) 
w 
DEPENDENT VARIABLE: RMTO 
SOURCE OF 
"IOOEL 5 
!::AAOR •• 
CCRFiECTEO -TOTAL 50 
SGURCE OF 
DOSE s 
5 T A T I ~ T I C A L Ao·N A L Y S I 5 
SC~=2 
SYSTE'4 13:30 MOND_AYo NOVEMBER 129 1979 24 
ANALYSIS OF VARIANCE PACCEDURE 
SUN OF SQUARES MEAN SQUARE F VALUE PR > F A-SQUARE -c.v. 
o.1.J2823a4 Q.02656477 28._75 0.0001 0.76156<; 61.9667 
0.04158425 0.00092409 STD DEY RHTO MEAN 
o.1744oeo9 0.03039892 0.0490!:~88 
ANOYA SS F VALUE PR > F 
o.13282384 28.75 0.0001 
DEPENDENT VARIABLE: s 
SOURCE OF SUM 
NOOEL 5 
ERRCQ ., 
CORRECTED TOTAL •• 
SGURCE OF 
DOSE s 
S T A T I S T ~ C A L ANALYSIS 
SEX.:::1 
SYSTEM 1~:30 MCNDAYo NOVEMBER 12• 1979 17 
ANALYSIS OF VARIANCE PROCEOUi:tE 
OF SQUARES MEAN SQUARE F VALUE PR > F A-SQUARE CAY. 
8.47800454 l a69560091 20.01 0.0001 o.699364 64.8418 
3.64444444 o.OB475o\.52 STO OEV s MEAN 
12.122448'i8 0.29112630 Oe448979'S9 
A.NOVA SS F VALUE PR > F 
8.47800.\.54 20.0 l 0.0001 
DEPENDENT VARIABLE! s 
SOURCE OF 
"40DEL s 
ERROR •• 
CCRRECTEO TOTAL so 
SOURCE DF 
DOSE s 
STATISTICAL AN·ALYSIS 
SEX=2 
SY STEN 13:30 MONDAY. NOVEMBER 12 0 1979 22 
ANALYSIS OF VARIANCE PRCCED~RE 
SUM OF SOU ARES - MEAN SQUARE F VALUE PR > F R;;,.SOUARE c.v. 
8.52287582 l.70457516 18. l 7 o.6~e11e 62.4877 
4.222222;;;:2 0 .09382715 STD DEV S MEAN 
12.7450<;904 0.30631219 o.~9ot9~0e 
ANOVA SS F VALUE PR > F 
8.52287582 la .11 0 .0001 
f-' 
I\) 
"' 
